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CHAPTER I 
INTRODUCTION 
Metastasis is believed to involve a series of sequential 
events which include intravasation, extravasation and 
invasion, during which tumor cells must penetrate various host 
tissue barriers. This has led to a hypothesis that metastasis 
may require the enzymatic degradation of structural components 
of the extracellular matrix and basement membrane. Consistent 
with this hypothesis, many studies have shown increased levels 
of proteolytic enzymes produced by tumor cells. These include 
metalloproteinases such as collagenase (Fessler et al. 1984), 
serine proteinases such as tissue type and urokinase type 
plasminogen activators (Moscatelli et al. 1980; Schmitt et al. 
1992), and several lysosomal proteinases including cathepsin 
B (Sloane et al. 1981; Recklies et al. 1982; Dufek et al. 
1984; Qian et al. 1989;) , cathepsin L (Gal and Gottesman, 
1986; Troen et al. 1988) and cathepsin D (Capony et al. 1987; 
Maudelonde et al. 1988). 
Among these proteinases which may play a role in the 
metastatic process, cathepsin B has been extensively 
investigated. Cathepsin B is capable of degrading many of the 
protein constituents in the extracellular matrix, such as 
f ibronectin, laminin, and type IV collagen and others (Sloane, 
2 
1990; Delaisse et al. 1991; Buck et al. 1992; Cardozo et al. 
1992) . Cathepsin B can also activate a number of latent 
extracellular proteinases such as procollagenase (Eeckhout and 
Vaes, 1977) and proplasminogen activator (Kobayashi et al. 
1991; Schmitt et al. 1992). Consequently, were cathepsin B to 
be secreted by tumor cells, it could cause the degradation of 
the structural barriers through which tumor cells must migrate 
during invasion and metastasis (Docherty et al. 1983). 
Elevated levels of cathepsin B are often associated 
with cancer (Sloane, 1990). In addition, cathepsin Bis not 
exclusively targeted to lysosomes in tumor cells. It has been 
reported to be in the nucleus (Pietras and Roberts, 1981) 
where it could act to modify proteins which regulate DNA 
replication and gene expression. Cell surface and secreted 
forms of cathepsin B are also well documented in malignant 
tumors. In rodents, levels of intracellular and secreted forms 
of cathepsin B have been correlated with metastatic potential 
in murine B16 melanoma variants (Sloane et al. 1981; Sloane et 
al. 1982; Qian et al. 1989), in BOX rat sarcoma variants 
(Koppel et al. 1984) and Lewis lung tumors (Takenaga, 1984), 
and in humans, in liver (Ohsawa et al. 1989), colorectal 
(Keppler et al. 1988a; Maciewicz et al. 1989; Sheahan et al. 
1989), gastric (Watanabe et al. 1989) and lung tumors 
(Kasafirek et al. 1990). Higher molecular weight latent forms 
of cathepsin B have been detected in body fluids of patients 
with primary liver cancer, ovarian cancer (Mort et al. 1983; 
3 
Dufek et al. 1984) and breast cancer {Petrova-Skalkova et al. 
1987). Forms of cathepsin B associated with the cell surface 
have been reported for human, rat, and murine tumors {Recklies 
et al. 1982; Mort et al. 1983; Koppel et al. 1984; Dufek et 
al. 1984; Petrova-Skalkova et al. 1987; Keren and LeGrue, 
1988), and have been correlated with tumor invasiveness and/or 
metastasis in humans {Weiss et al. 1990) and rodents {Sloane 
et al. 1986). These and similar findings suggest a direct or 
indirect role for cathepsin B in facilitating tumor metastasis 
through its ability to degrade the extracellular matrix and to 
release tumor cells from solid tumors. However the molecular 
basis for the increased production of cathepsin B and its 
abnormal localization to cell membranes, nuclei and secretory 
vesicles of tumor cells is unknown. 
Eukaryotic pre-mRNAs undergo a series of nuclear 
processing events. Splicing of all intron sequences must 
occur with a high degree of accuracy in order for functional 
proteins to be generated. However, flexibility in the 
selection of a splice site, which forms the basis for. the 
alternative splicing, is not unexpected. Alternative splicing 
can produce different but related messages. The variant 
proteins derived from these messages could then be targeted to 
different cellular and subcellular locations {Kwiatkowski et 
al. 1986; Johnson et al. 1990; Alt et al. 1980). Alternative 
splicing can also produce messages which vary in their 5 1 - or 
3 1 -untranslated regions {UTRs) and consequently affect mRNA 
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stability and translational efficiency (Kozak, 1991a,b; 
Brawerman, 1987) . Thus, alternative processing of the 
cathepsin B pre-mRNA may be one of many possible factors which 
can be advanced for differences in cathepsin B protein levels 
between normal tissues and tumors, and for the presence of 
unusual tumor forms of cathepsin B protein which might be 
directed to the nucleus, the cell surface or the cell 
exterior. 
Cathepsin B mRNA cloned from human kidney is 
heterogeneous due to alternative processing of the 5 ' - and 3 ' -
ends of the primary transcript, resulting in mRNAs which 
contain alternative 5'- and 3 1 -UTRs (Gong et al. 1993). The 
variable removal of exon 2 produces transcripts which differ 
by 88 bases in the lengths of their 5'-UTR. The sequence of 
exon 2 has features which could decrease the translational 
efficiency of the transcript. Consequently, were exon 2 more 
frequently absent from the 5'-UTR of tumor cell cathepsin B 
mRNAs, it could explain higher levels of cathepsin B in 
tumors. In this present work we have found that some human 
tumors contain a third class of transcripts which lack exon 3. 
As exon 3 contains the coding sequence for the signal peptide 
required to initially direct cathepsin B to lysosomes, and a 
portion of the inhibitory propeptide, mRNA lacking exon 3 
could be responsible for the presence of active cathepsin B 
forms at the cell surface and/or within the nuclei of human 
tumors. 
5 
It is my hypothesis that the higher levels of cathepsin 
B found in tumor cells is due to differences in cathepsin B 
pre-mRNA processing between normal tissues and tumor cells. 
Therefore, the specific aims of the present research are: 1) 
to determine relative abundances of different mRNA forms 
between normal human tissues and human tumors; 2) to determine 
translational activities of the various cathepsin B mRNAs 
which differ in the length of their 5'-UTRs in an in vitro 
translation assay; 3) to clone the transcript lacking exon 3 
and to study its translational potential in an in vitro assay 
system; and 4) to determine whether the putative protein 
products of messages which lack exon 3 possess peptidolytic 
activity. 
CHAPTER II 
REVIEW OP THE RELATED LITERATURE 
A. Cellular Proteinases 
Proteases include two groups: exopeptidase (peptidases) 
which cleave either amino- or carboxyl-terminal amino acids or 
dipeptides from proteins, and endopeptidases (proteinases) 
which cleave peptide bonds in the interior of protein 
molecules. However, some proteases can have both exo- and 
endo-peptidase activities. 
Proteases can also be subdivided into five classes based 
on the mechanisms of peptide bond cleavage catalyzed by their 
active center (Barrett, 1980a): serine proteinases, cysteine 
proteinases, aspartic proteinases, metalloproteinases, and a 
fifth category which includes enzymes with different or 
undetermined catalytic mechanisms. Each of the first four 
classes will be briefly discussed, and then cathepsin B will 
be introduced. 
1. serine Proteinases 
Serine proteinases include trypsin, chymotrypsin, 
elastase, coagulation factors, plasmin, cathepsin G, chymases, 
tryptases, plasminogen activators and others. Sequence 
6 
7 
homologies among the serine proteinases suggest that they may 
have a common evolutionary origin (Hartley, 1970). Serine 
proteinases all have a serine in their active sites and are 
active at neutral pH without the need of cofactors. An 
adjacent histidine residue which functions as a general acid-
general base catalyst is essential for the activity of these 
enzymes (Walsh, 1979). They are synthesized as inactive 
processors that require limited proteolysis for activation. 
Serine proteinases, which participate in coagulation, are 
controlled by a cascade of activating enzymes and a system of 
protein proteinase inhibitors. Serine proteinases that have 
been of particular interest in cancer metastasis are plasmin 
and the pro-urokinase and tissue type plasminogen activators. 
2. cysteine Proteinases 
Cysteine proteinases contain a cysteine residue in their 
active sites. An adjacent histidine residue which functions 
as a general acid-general base catalyst is also essential for 
the activity of this class of enzymes {Topham et al. 1990). 
This subclass of proteinases includes lysosomal enzymes 
(cathepsin B, Hand L) (Barrett, 1980b), the plant proteinase 
papain, and the cytosolic calcium-activated neutral 
proteinases, calpains (Barth and Elce, 1981; Dayton and 
Schollmeyer, 1981). The amino acid sequence of papain and of 
cathepsin B and H have been found to be significantly 
homologous (Takio et al. 1983) . However, cathepsin H and 
papain appear more closely related than are papain and 
8 
cathepsin B or cathepsin H and cathepsin B. The active sites 
of cathepsin B and papain are functionally homologous as well 
as structurally homologous (Bajkowski and Frankfater, 1983a; 
Bajkowski and Frankfater, 1983b) . The lysosomal cysteine 
proteinases are synthesized as larger inactive precursors 
which undergo proteolytic maturation. Their mature forms are 
normally confined to the lysosome and thought to play an 
important role in intracellular protein degradation. The 
lysosomal cysteine proteinases exhibit pH optima of about 6. O, 
and are unstable above pH 7 (Barrett and Kirschke, 1981; 
Barrett, 1984). However, some lysosomal cysteine proteinases, 
such as cathepsin B, are secreted into extracellular 
environment by tumor cells, and appear to retain activity at 
and above pH 7.0 (Mullins and Rohrlich, 1983). 
3. Aspartic Proteinases 
Members of the family of aspartic proteinases include 
pepsin, renin and cathepsin D. All of these enzymes contain 
aspartate in their active sites, and are synthesized as 
inactive precursors which are processed either 
autocatalytically (e.g. pepsin) or by other enzymes (e.g. 
renin) to remove an N-terminal propeptide. Pepsin, which 
functions in the acidic milieu of the stomach, is responsible 
for the initial steps in protein digestion. cathepsin D is a 
lysosomal enzyme and plays an important role in intracellular 
proteolysis in the acidic environment of the lysosome. Renin 
is thought to have originated from the hypothetical cathepsin 
9 
D-like archetype. However, unlike cathepsin D it is stable 
and active at neutral pH, and is highly specific for the Leu-
Leu bond that generates angiotensin I from angiotensinogen 
(Reid et al. 1978). 
4. Metalloproteinases 
Metalloproteinases are characterized by the presence of 
zn2+ in their active sites. Examples of this group include 
pancreatic carboxypeptidase, thermolysin and collagenases. 
The metalloproteinases have a neutral to slightly alkaline pH 
optimum, and their activities can be inhibited by EDTA and 
thiols. They seem well suited to function extracellularly. 
Type IV collagenase, a metalloproteinase, has been found 
to be secreted by a variety of malignant tumors (Liotta et al. 
1982; Fessler et al. 1984). The type IV collagenase degrades 
the basement membrane type IV collagen molecule at a single 
site in the helical domain at about one fourth the distance 
from the N-terminal end (Fessler et al. 1984). Accordingly, 
the enzyme may be able to decompose the collagen network of 
basement membrane and thus facilitates penetration by tumor 
cells. 
B. cathepsin B 
Cathepsin B is a cysteine proteinase located in the 
lysosomes of mammalian cells. Cathepsin B has been isolated 
from tissues of various mammalian species, including rat liver 
(Otto, 1971), bovine spleen and liver (Otto, 1971), and human 
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spleen and liver (Barrett, 1973). Using immunochemical 
methods, cathepsin B has been located within macrophages 
(Howie et al. 1985), fibroblasts (Mort et al. 1981), neurons 
(Howie et al. 1985), myocytes (Bird et al. 1985) and 
epithelial cells (Howie et al. 1985) of various tissues. 
Cathepsin B is thought to play an important role in a number 
of physiological and pathological processes including: 
degradation of endocytosed proteins (Huisman et al. 1974; 
Bystryn and Perlstein, 1982) and intracellular proteins (Kar 
and Pearson, 1977; Shaw and Dean, 1980); processing of 
secreted proteins (Quinn and Judah, 1978), enzymes (Figarella 
et al. 1988) , hormones (Docherty and Steiner, 1982) and 
neuromodulatory polypeptides (Docherty and Steiner, 1982) ; 
tissue resorption and remodeling (Bayliss and Ali, 1978) ; 
inflammation (Daries et al. 1978) and mediation of hormonal 
response (Pietras et al. 1975). At present, the full spectrum 
of the biological role of cathepsin B is still not very clear 
but its broad tissue distribution suggests it has many 
important functions. 
Cathepsin B is both an endopeptidase and a peptidyl 
dipeptidase (Aronson and Barrett, 1978). Below pH 5, 
cathepsin B is an exopeptidase (Polgar and Csoma, 1987) 
catalyzing the successive removal of dipeptides from the 
carboxyl terminus of proteins (Aronson and Barrett, 1978). 
Between pH 5 and 7, cathepsin B shows endopeptidase activity 
(Polgar and Csoma, 1987) with a broad specificity (Barrett and 
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Kirschke, 1981; Mason, 1989). Synthetic substrates containing 
the -Arg-Arg- sequence, such as Benzoyl-L-arginine-L-
arginine-2-naphthylamide, are extremely sensitive to cathepsin 
B (McDonald and Ellis, 1975). Fluorogenic and chromogenic 
synthetic substrates are the most common substrates used in 
enzyme assays for determination of cathepsin B activity 
(Barrett, 1973; Bajkowski and Frankfater, 1975). 
Mature cathepsin B has a molecular weight of 27,000 -
29,000. It is derived from a larger precursor, procathepsin 
B, which in its glycosylated state has a molecular weight of 
about 43,000 (Barrett, 1987; Nishimura et al. 1988). 
Proteolytic processing of the precursor yields both an active 
single chain form and a two chain form (Hanewinkel et al. 
1987). Procathepsin B can also be activated in vitro by 
limited proteolytic cleavage with pepsin (Achkar et al. 1990; 
Rowan et al. 1992). Procathepsin Bis in turn derived from 
preprocathepsin B which is synthesized on the rough 
endoplasmic reticulum. Preprocathepsin B is converted to 
procathepsin B by cleavage with a signal peptidase which 
removes the N-terminal signal peptide in the lumen of the 
rough endoplasmic reticulum. 
Procathepsin B is directed to the lysosome where it is 
converted to biologically active mature forms (McDonald and 
Ellis, 1975). In fibroblasts, it is known that mannose-6-
phosphate receptors segregate newly synthesized lysosomal 
enzymes from secretory proteins in the trans Golgi network. 
12 
The lysosomal enzyme-receptor complex is delivered to an 
intermediate acidified compartment where dissociation of the 
complex occurs. Receptors are then returned to the Golgi 
apparatus and cell surf ace for reuse while lysosomal enzymes 
in turn are transferred to the lysosome. 
There have been many reports of cathepsin B-like 
activities associated with polypeptides of Mr greater than 
26, 000-27, ooo. Steiner and coworkers have shown that 125I-
tyrosyl-Arg-ArgCH2Cl, a cathepsin B substrate analog, 
covalently labeled three polypeptides of Mr 39, 000, 31, 500 and 
25,000 in rat islet cells (Docherty et al. 1983) and in a 
transplantable rat insulinoma (Docherty et al. 1984). The Mr 
= 31,500 form cross-reacted with anti-rat liver cathepsin B 
antibodies. Pepsin treatment of the Mr = 39, 000 form 
converted it to a 31,500 protein which was also precipitated 
with anti-rat liver cathepsin B antibodies, suggesting that 
the 39,000 and 31,500 polypeptides are related as precursor to 
product. These workers also found that cathepsin B in rat 
islets is synthesized initially as a precursor of approximate 
Mr= 43,000. In the insulinoma the Mr= 39,000 form was found 
in insulin secretory granules, the Mr = 31,500 form was found 
in secretory granules and lysosomes, whereas the Mr = 25,000 
species was only found in the lysosomal fraction. 
Consequently, it has been suggested that the larger percursor 
farms of cathepsin B are sorted into secretory granules, 
possibly as a consequence of their incomplete targeting to 
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lysosomes via the mannose-6-phosphate pathway. 
Preprocathepsin B cDNAs of human (Fong et al. 1986), rat 
(Chan et al. 1986) and mouse (Fong et al. 1986) have been 
cloned and sequenced. Each predicts a primary structure of 
339 amino acids. The amino acid sequences of the rat and 
mouse enzymes are similar, with 90% identity. The human and 
rat amino sequences are 84% identical in the regions of the 
mature proteins, and about 50% identical in the preproregions 
and c-terminal peptide extensions. 
The entire human cathepsin B gene has been cloned and its 
structure elucidated. The 350 nucleotides preceding the 
transcription start site, large portions of introns 1 and 2 
(Gong et al. 1993), and all 12 exons have been sequenced (Fong 
et al. 1986). There are several Spl binding sites in the S'-
flanking region and in intron 1 but no TATA box appropriately 
positioned with respect to the transcription initiation site. 
Cathepsin B cDNA cloned from human tissues is 
heterogeneous due to differences in processing of the 5' and 
3'-ends of the pre-mRNA (Figure 1). Alternative splicing, 
"exon 2 skipping", produces mRNAs which differ by 88 bases in 
the lengths of their 5 1 -untranslated regions. The occasional 
selection of an alternative intron donor site in exon 11 can 
result in the loss of an adjacent polyadenylation signal in 
exon 11 and termination after a downstream signal in exon 12. 
This produces two kinds of transcripts (2. 3Kb and 4. OKb) which 
vary in the lengths of their 3'-untranslated regions. 
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Figure 1. Organization of the cathepsin B gene and its mRNA transcript. Intron 
positions (f) and polyadenylation signals (A) are identified. The coding regions for 
the prepeptide, activation propeptide and mature enzyme are indicated by boxes. Also 
shown are the sizes of the first six exons. 
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The mouse cathepsin B gene and its 5 '-upstream region has 
also been cloned (Qian et al. 1991b). The gene has 10 exons 
and 9 introns spanning about 20 kb. Exon 10 contains three 
potential polyadenylation sites which are alternatively used 
in transcription of cathepsin B mRNA in B16 melanoma. Like 
that of human cathepsin B, the 5 1 upstream region of the mouse 
cathepsin B gene has several Spl binding sites and lacks a 
TATA box in the immediate vicinity of the transcription start 
site (Qian et al. 1991b). 
c. correlation Between cathepsin B Expression and Malignant 
Tumors 
Sufficient evidence has accumulated to implicate 
proteolytic enzymes as playing an important role in tumor 
metastasis. Proteinases, either on the cell surface or 
released by tumor cells, are thought to facilitate tumor cell 
colonization (Yee and Shiu, 1980; Mainferme et al. 1985) . 
Consequently, many studies have focused on enzymes that are 
known to degrade connective tissue constituents, such as 
collagenase (Liotta et al. 1979), neutral proteinase 
(Edmonds-Alt et al. 1980), plasminogen activator (Laug et al. 
1983) , glycosidase (Kramer et al. 1986) and cathepsin B 
(Recklies et al. 1982; Qian et al. 1989). There may also 
exist a proteolytic cascade in which one or more proteinases 
act in concert and a newly activated protein in turn may 
activate others (Kramer et al. 1986; Kobayashi et al. 1992). 
In the case of cathepsin B, increased enzyme activity has 
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been found in a large number of .metastatic tumors. Elevated 
cathepsin B activity has been reported in humans for liver 
(Dufek et al. 1985), colorectal (Dufek et al. 1984; Keppler et 
al. 1988a; Maciewicz et al. 1989; Sheahan et al. 1989), 
gastric (Watanabe et al. 1989), breast (Poole et al. 1978; 
Recklies et al. 1980; Dengler et al. 1991; Lah et al. 1992), 
lung (Kasafirek et al. 1990) and cervical cancers (Pietras and 
Roberts, 1981). In addition, positive correlations have been 
observed between intracellular levels of cathepsin B and the 
metastatic phenotype in the murine B16 melanoma variants 
(Sloane et al. 1981; Sloane et al. 1982), in cultured three 
Lewis lung clones (Takenaga, 1984) and in cultured BDX rat 
sarcoma variants (Koppel et al. 1984). The presence of the 
elevated cathepsin B activity in tumor cells suggests a direct 
or indirect role for this enzyme in the degradation of the 
extracellular matrix and in the release of tumor cells from 
solid tumors. cathepsin B can degrade fibronectin, laminin 
and type IV collagen (Sloane, 1990), and can activate latent 
collagenase (Eeckhout and Vaes, 1977) and pro-urokinase type 
plasminogen activator (Kobayashi et al. 1991). 
Further evidence in support of a role for cathepsin B in 
tumor invasion is the observation of increased cathepsin B 
activity in plasma membrane of tumor cells, at the margins of 
actively growing tumors in direct contact with the 
extracellular matrix, and the observation of the release of 
cathepsin B from tumor cells. Cathepsin B act~vity has been 
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found in the plasma membrane fraction from anaplastic sarcoma 
in BOX rat (Koppel et al. 1984}, from murine fibrosarcomas 
(Keren and LeGrue, 1988}, from mouse B16 melanoma variants in 
proportion to the metastatic potential of the variants (Sloane 
et al. 1986}, and from a human pancreatic adenocarcinoma 
(Zucker et al. 1985}. Cathepsin B activity is localized at 
the invasion front of a rabbit V2 carcinoma (Graf et al. 
1981}. The secreted enzymes are very similar to lysosomal 
cathepsin B in terms of their reactivity to synthetic 
substrates. It was shown that cultured explants of malignant 
human breast tumors released eleven times more cathepsin B 
activity than normal breast tissue or nonmalignant tumors 
(Poole et al. 1978; Recklies et al. 1980). Other reports 
indicated elevation of cathepsin B activity in the serum of 
women with genital tract cancer especially in those patients 
with invasive carcinomas (Pietras et al. 1979; Pietras and 
Roberts, 1981}, in malignant ascites fluid from patients with 
primary liver and ovarian cancer ( Mort et al. 1983; Dufek et 
al. 1984) , in pleural effusions from patients with breast 
cancer (Petrova-Skalkova et al. 1987), and in conditioned 
media from human and murine tumors (Recklies et al. 1982; Mort 
et al. 1983; Qian et al. 1989). 
The secreted cathepsin B-like enzyme activities are 
different from lysosomal cathepsin B in that they have higher 
molecular weights. Two extracellular high molecular weight 
forms of human cathepsin B with Mr 40,000 have been observed, 
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one is latent, the other active. In ascitic fluid and culture 
medium of ascites cells from cancer patients, a latent form of 
cathepsin B was discovered which could be activated by pepsin 
pretreatment (Mort et al. 1981). In addition, malignant human 
breast tumors in organ culture release a high molecular weight 
form of cathepsin B that was detected by its ability to 
hydrolyze synthetic substrates for which lysosomal cathepsin 
B has high specificity (Mort et al. 1980). The advantages 
that tumor cells gain by secreting latent and high molecular 
weight forms of lysosomal proteinase may be related to the 
instability of low molecular weight lysosomal form above pH 7, 
resulting in rapid denaturation and inactivation in serum. In 
contrast, high molecular weight latent and active forms of 
cathepsin B are more stable under these same conditions (Mort 
and Rechlies, 1986). In addition, secretion of a latent 
enzyme, which is then activated some distance from tumor 
cells, may protect the enzyme from inactivation by endogenous 
inhibitor while undergoing transport to its site of action. 
Thus, the active, high molecular weight secreted form of 
cathepsin B is not inhibi table by plasma proteinase inhibitor, 
a2-macroglobulin, whereas the lysosomal form is inhibitable 
(Mort and Rechlies, 1986). Schultz and his associates found 
that leupeptin, an inhibitor of cathepsin B did not prevent 
the invasion of B16-F10 melanoma cells across basement 
membrane in vitro (Persky et al. 1986) or lung colonization in 
vivo (Ostrowski et al. 1986). In contrast, Belleli et al 
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(1990) recently found that papain-inununized mice possessed 
serum antibodies which cross-react with cathepsin B like 
endopeptidase isolated from B16 melanoma cells. The growth 
rate, invasion and metastasis of both B16 melanoma and the 
Lewis lung carcinoma were inhibited in mice immunized with 
papain. It may be that the secreted and/or membrane 
associated forms of cathepsin B, which might be insensitive to 
inhibition by leupeptin but can react with anti-papain 
antibodies, play a role in the metastasis of B16 melanoma 
cells. 
The molecular basis for increased cellular and secreted 
levels and altered cellular distribution of cathepsin B in 
tumor cells is not well understood. Possible factors may 
include differences in transcription, post-transcriptional 
processing, translation, and post-translational processing of 
cathepsin B. Comparisons of mRNA levels for five lysosomal 
proteinases, cathepsin B, D, H, L, and S in B16 melanoma 
cells, in rat W-256 carcinoma cells, and in normal rodent 
tissues revealed that only the mRNA for cathepsin B is 
elevated in the malignant tumors (Qian et al. 1989; Qian et 
al. 1990). A correlation between the metastatic potentials of 
several B16 melanoma variants and cathepsin B mRNA levels has 
been observed. No evidence was found for gene amplification 
or gross chromosome rearrangement, or for the presence of more 
than one gene for cathepsin B in melanoma cells. These 
findings together with recent results of nuclear run off 
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assays (F. Qian, unpublished results) suggest that in these 
cells cathepsin B expression is regulated, at least in part, 
at the level of RNA transcription. 
In addition to the normal 2.2 Kb transcript, two larger 
transcripts ( 4. o and 5. o Kb) were found in B16 melanomas. 
These larger transcripts were not seen in normal mouse tissues 
(Qian et al. 1989). A comparison of the cDNAs derived from 
the larger transcripts with the cathepsin B gene and cDNA 
derived from normal message revealed that all three 
transcripts from mouse melanoma cells encoded for the same 
form of cathepsin B and differed only in the lengths of their 
3 1 -untranslated regions. The differences in the 3'-UTRs was 
due to the utilization of alternative polyadenylation signals 
during the processing of the 3'-end of cathepsin B pre-mRNA, 
the larger transcripts resulting from the occassional use of 
downstream polyadenylation signals in melanoma cells (Qian et 
al. 199lb; Qian et al. 1991c) • Thus, the secretion and 
altered distribution of cathepsin B in murine melanoma cells 
is not due to alteration in the gene or in the pre-mRNA 
processing, but more likely due to aberrant proenzyme 
processing and sorting. 
Mannose-6-phosphate receptors and mannose-6-phosphate-
containing sugar side chains are required for correct delivery 
of enzymes to lysosomes (Kornfeld, 1987). Alterations in N-
linked oligosaccharides have been found in proprecathepsin D 
secreted by MCF7 mammary cancer cells (Capony et al. 1989). 
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The secretion of procathepsin L by Kirsten sarcoma virus-
transformed fibroblasts {KNIH cell) is reported to be due to 
poor binding of cathepsin L to mannose-6-phosphate receptor, 
together with saturation of the mannose-6-phosphate receptor 
resulting from cathepsin L overexpression {Dong et al. 1989). 
Moloney murine sarcoma virus-transformed fibroblasts {MMSV 
cell) express 3-4 fold higher levels of cathepsins B, D, and 
L, but not Hand S {Qian et al. 199la). In addition, MMSV 
cells appear to have a general defect in lysosomal enzyme 
sorting which causes the increased secretion of latent 
cathepsin B, cathepsin L and an active ~-glucuronidase (Achkar 
et al. 1990). This enhanced lysosomal enzyme secretion was 
correlated with an absence of cell surf ace mannose-6-phosphate 
receptor activity (Achkar et al. 1990) and an alkalinization 
of vacuolar compartments, which should prevent lysosomal 
enzyme-mannose-6-phosphate receptor uncoupling (Pracht et al. 
1991). Agents which acidified MMSV cells strongly inhibited 
cathepsin B secretion and restored cellular levels to amounts 
seen in normal fibroblasts. These results agree with the 
finding that estrogen increases the secretion of cathepsins D, 
L, and B by human mammary carcinoma MCF-7 cells by down-
regulating mannose-6-phosphate receptor expression (Mathieu et 
al. 1991) . 
In contrast to the above results in mouse, cathepsin B 
expression in human tissues may be regulated at the level of 
mRNA processing. Multiple forms of the cathepsin B mRNAs 
22 
which differ in their 3 1 and s•-untranslated regions were also 
found in human tissues. These different forms of mRNA arise 
from alternative splicing of the 5' and 3 '-untranslated 
regions (Figure 1). Examples of messages with alternative 5 '-
untranslated regions have been described (Young et al. 1981; 
Lowe et al. 1987; Shen et al. 1988; Nonaka et al. 1989; 
Horiuchi et al. 1990; Waterhouse et al. 1990). Many reports 
have indicated that changes in the s•-noncoding sequence of a 
message can affect the translational efficiency of the message 
(Rao et al. 1988; Horiuchi et al. 1990; Waterhouse et al. 
1990; Grens and Scheffler, 1990). Alternative utilization of 
multiple polyadenylation signals in 3'-end processing of pre-
mRNA has also been described (Setzer et al. 1980; Tosi et al. 
1981; Aho et al. 1983; Sanke et al. 1988). Modifications at 
the 3'-ends of messages have been shown to affect the 
translational capacity (Grens and Scheffler, 1990) and rates 
of mRNA turnover (Brawerman, 1987; Ross, 1988) in some cases. 
The alternative splicing of pre-mRNA and its functional 
effects are reviewed in next section. 
D. Alternative Pre-mRNA Splicing 
Eukaryotic pre-messenger RNAs undergo a series of nuclear 
processing events. In addition to S' capping with 7-methyl 
guanosine (Salditt-Georgieff et al. 1980), and the addition of 
a poly A tail to the 3' end of the nascent transcripts 
(Birnstiel et al. 1985), introns must be precisely excised and 
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exons correctly ligated to avoid disrupting the open reading 
frame. Not unexpectedly, the pre-mRNAs can sometimes be 
spliced in more than one way. In recent years, alterative 
pre-mRNA splicing has emerged as a powerful post-
transcriptional mechanism for regulating gene expression. By 
utilizing different splice sites within the same precursor 
RNA, multiple transcripts and corresponding protein products 
can be generated from a single gene. In this section, 
alternative splicing and its function will be reviewed after 
briefly introducing constitutive splicing. 
1. Constitutive Splicing 
The splicing reaction has been extensively studied in 
cell-free systems that used exogenous pre-mRNA substrates 
(Grabowski et al. 1984; Krainer et al. 1984; Ruskin et al. 
1984 Lambowitz, 1989). Splicing is a multistep process 
involving two successive transesterification reactions (Sharp, 
1987). Initially, cleavage occurs at the 5' donor splice 
site, and the 5' end of the intron is joined to an adenosine 
residue located within the intron (branch-point), giving rise 
to a lariat form of the intron. The second 
transesterification reaction between the 5 1 splice donor and 
J' splice acceptor sites results in ligation of the exons and 
release of the lariat intron. Comparison of sequences of the 
corresponding genomic DNA with that of cDNA revealed that 
moderately conserved and short consensus sequences exist at 
intron-exon boundaries (Mount, 1982). The 5 1 donor splice 
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site consensus is AG/GUPuGU (where the intron-exon boundary is 
denoted by the backslash), and the 3' acceptor splice site 
consensus sequence is P.yAG/G. Of these bases, the most highly 
conserved are the first two and last two bases of the intron. 
Al though important, these consensus sequences are not 
sufficient to define efficient splice sites because similar 
sequences are found in positions other than actual splice 
sites. Some of these cryptic sites can be activated when the 
normal splice sites are mutated ( Ruskin et al. 1985; Aebi et 
al. 1987). Several observations had led to a suggestion that 
small ribonucleoprotein particles (snRNPs) somehow assisted in 
the splicing reaction. First, the short consensus sequence at 
the 5' end of introns was found to be complementary to a site 
near the 5' end of the small nuclear RNA (snRNA), called Ul 
(Lerner et al. 1980). Second, snRNAs were found in nuclear 
extracts as part of large particles containing pre-mRNA 
(Steitz et al. 1988). Subsequently, Ul, U2, U4, US and U6 
have been purified, sequenced and shown to be necessary for 
splicing (Guthrie, 1991; Ruby and Abelson, 1991). All of 
these snRNAs are associated in the nucleus with six to ten 
proteins to form snRNPs. These snRNPs assemble with pre-mRNA 
and additional proteins to form a large particle, called a 
spliceosome. 
The total population of pre-mRNA in the cell nucleus, 
known as heterogeneous nuclear RNA (hnRNA), is found in 
association with a discrete set of proteins, forming repeating 
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structures termed hnRNP particles. These are visualized as a 
linear array of globular monoparticles along each pre-mRNA 
molecule (Dreyfuss, 1986). Cleavage of the linker RNA by 
brief RNase treatment releases single particles that sediment 
at 30-405. These particles contain a segment of hnRNA about 
700 nucleotides long and core hnRNP proteins, Al, A2, Bl, B2, 
Cl, and C2, in a well-defined stoichiometry (Conway et al. 
1988). Because of their abundance and association with hnRNA, 
hnRNP proteins are thought to be involved in the packing and 
posttranscriptional processing of all pre-mRNA. In vitro 
studies under splicing conditions showed sequence-specific 
binding of hnRNP protein Al to the 3' splicing site (Swanson 
and Dreyfuss, 1988). In nuclear extracts, UV-induced cross-
linking of hnRNP proteins Al and C to pre-mRNA requires the 
presence of Ul and U2 snRNPs, suggesting that specific 
interaction take place between hnRNP and snRNP particles 
(Mayrand and Pederson, 1990). Prevention of in vitro splicing 
reaction by the antibodies against hnRNP proteins indicated a 
requirement of hnRNP proteins during splicing (Choi et al. 
1986; Sierakowska et al. 1986). 
The interactions of the cis-acting elements in pre-mRNA 
with the trans-acting protein and snRNA factors are necessary 
for constitutive splicing. These interactions are thought to 
be altered and/or regulated to allow for alternative splicing. 
2. Modes of Alternative Splicing 
Smith et al (1989) have devised a scheme for classifying 
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alternative splicing based upon a wide variety of possible 
regulated events which can give rise to different mRNA 
transcripts from the same initial gene. 
Retained Intron Introns can either be spliced out or 
retained in the mature RNA. The retained intron can result in 
a premature termination, an altered amino acid segment due to 
frameshift, or the insertion of a peptide if the open reading 
frame is maintained. Premature termination or frameshift may 
cause functionally different products to be made or may 
produce no functional product. Such examples are found in the 
genes for fibronectin (Schwarzbauer et al. 1987) and the A-
chain of platelet derived growth factor (Tong et al. 1987). 
Alternative s• Donor Sites and 3 1 Acceptor Sites 
Alternative utilization of 5' donor and/or 3' acceptor sites 
can excise introns of different lengths, resulting in retained 
exons of different sizes. Again, this can give rise to the 
insertion or deletion of a small peptide if the reading frame 
is maintained, or frameshifting and premature termination. 
Alternative Promoters and Polyadenylation Sites In some 
cases, a gene may contain more than one promoter or more than 
one poly A attachment site. The mRNAs which differ in their 
5 1 and 3' ends can result from differential utilization of 
more than one promoter or more than one polyadenylation 
signal. This can lead to variations in the amino acid 
sequence of the amino- or carboxyl-terminals of a protein, or 
to variations in the 5 1 and 3 1 untranslated regions of the 
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message. Utilization of alternative promoters dictates the 
splicing pattern of myosin light chain gene (Periasamy et al. 
1984), while an example of alternative 3 1 end exons resulting 
from the selection of different polyadenylation sites is found 
in a-tropomyosin transcripts (Helfman et al. 1986). 
Mutually Exclusive Exons Internal exons are sometimes 
used in a mutually exclusive manner. One member of the pair 
is always spliced into the mRNA, but never both. Thus, the 
two exons are never spliced together, nor are they both 
skipped. Examples of such splicing are found in genes for a 
and~ tropomyosins (Helfman et al. 1986; Goodwin et al. 1991). 
Isof orms TM-Sa and TM-Sb of a-tropomyosin are due to 
alternative inclusion of exon Ga and 6b respectively. The 
differences in the amino-acid sequence encoded by these 
alternate exons affects the act in-binding pattern of the 
tropomyosin. 
Cassette Exons Some cassette exons can be included or 
excluded (skipped} . This can lead to insertion of small 
peptide segment, premature termination, or a shift of reading 
frame. An example of such cassette exons is found in the 
troponin-T gene (Breitbart and Nadal-Ginard, 1987). The 
presence of five cassette exons at S' end of the gene give 
rise to hypervariability within the N-terminal region of 
troponin-T. 
3. Factors Affecting Splicing-site Selection 
Splicing of all intron-containing pre-mRNAs must occur 
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precisely in order to generate functional proteins. Authentic 
splicing sites, which exhibit sequence conservation, are 
accurately selected and matched by poorly understood 
mechanisms. On the other hand, flexibility in the selection 
of splice sites forms the basis for alternative splicing, an 
important mechanism for posttranscriptional control of gene 
expression. Thus, a large number of genes ·can express several 
related, but structurally and functionally distinct protein 
isoforms. The corresponding mRNAs arise by selection of 
alternative splice sites, a process that is often subject to 
tissue-specific or developmental control. The molecular 
mechanisms responsible for the specificity of constitutive and 
alternative splice-site selection are not well understood. 
Some cis- and trans-acting factors have been reported to be 
involved in splice-site selection, some essential for 
splicing, others affecting the efficiency with which a splice 
site is utilized. RNA secondary structure is also shown to 
affect splice-site selection. 
Cis-Actinq Factors The 5' splice site acting as a cis-
splicing element is highly conserved (Ohshima and Gotoh, 1987; 
Shapiro and Senapathy, 1987). Mutations within the 5' GU 
dinucleotide at the intron boundary inhibit in vitro splicing 
(Aebi et al. 1987; Treiman et al. 1983), and often cause 
activation of nearby cryptic splice sites in vivo. Variations 
of the 5' splice-site consensus outside of the GU do not 
absolutely impair splicing, but can affect the efficiency with 
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which the splice-site is used. Usually, mutation of 5' splice 
sites towards the consensus improves their competitive 
efficiency {Aebi et al. 1986; Eperon et al. 1986; Zhuang et 
al. 1987; Mayeda and Ohshima, 1988). 
The 3 ' splice-site consensus is another cis-acting factor 
which can affect the splicing. The AG dinucleotide at the 
intron-exon boundary is absolutely conserved {Mount, 1982; 
Padgett et al. 1986; Ohshima and Gotoh, 1987). The point 
mutation or deletion of the AG dinucleotide always inhibits 
splicing to the mutated splice site {Aebi et al. 1986; Lamond 
et al. 1987). However, in some cases, this mutation could 
result in utilization of the next downstream AG dinucleotide 
as the 3 1 splice site. 
In addition to 5 1 and 3 1 splice site consensus, branch-
point sequence and location have also been shown to affect the 
splicing. The branch-point consensus is commonly found 20-40 
nt upstream of the 3 1 splice site {Smith and Nadal-Ginard, 
1989; Helfman and Ricci, 1989). Deletion of the sequence 
between the branch-point and 3' splice site could result in 
alternative splice-site selection { Helfman et al. 1990; Guo 
et al. 1991). The most highly conserved position in the 
consensus is the A at the site of branch formation. Point 
mutations of the branch-point sequence often have no effect 
upon splicing due to the activation of a nearby cryptic branch 
point {Padgett et al. 1985; Reed and Maniatis, 1985; Ruskin et 
al. 1985). It has been found that some alternatively spliced 
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introns contained multiple branch points associated with a 
single acceptor site (Gattoni et al. 1988; Noble et al. 1988; 
Helfman and Ricci, 1989) demonstrated that the utilization of 
different branch points plays a crucial role in the alterative 
splicing of the SV40 pre-mRNA. The large-T and small-t mRNAs 
result from the use of two alternative 5' splice sites joined 
to a single shared 3' splice site. 
'!'rans-Acting Factors The observation that identical 
primary transcripts are processed along alternative splicing 
pathways, according to cell type or stage of development, 
clearly demonstrates differences in the trans-splicing 
environments of these cells (Medford et al. 1984; Bretibart et 
al. 1985; Leff et al. 1987; Breitbart and Nadal-Ginard, 1987; 
Tsurushita et al. 1988). Such variability in the splicing 
environments is likely determined by specific splicing 
factors. Some RNA and protein factors which are required for 
constitutive splicing are present in variant forms. These 
variant forms may increase the possibility for regulation of 
alternative splice-site selection. 
snRNPs, Ul, U2, US, and U4/U6, have all been shown to be 
essential for splicing by a combination of antibody and RNase 
H mediated degradation experiments (Krainer et al. 1984; 
Kramer et al. 1984; Black et al. 1985; Chabot et al. 1985; 
Black and Steitz, 1986; Berget and Robberson, 1986). Some 
snRNAs showed heterogeneity. For example, about 15% of the 
total human Ul RNAs may be composed of variant sequences 
31 
(Lund, 1988). In addition, in mouse, multiple Ul RNAs have 
been detected and appear to be developmentally regulated (Kato 
and Harada, 1985; Lund et al. 1985). Likewise, U4 RNAs are 
regulated in a developmental and tissue-specific manner in 
chicken and Xenopus (Lund and Dahlberg, 1987; Krof et al. 
1988). Sequence heterogeneity of U2 RNA has not been detected 
but it is thought that posttranscriptional base modification 
may be developmentally regulated and lead to heterogeneous U2 
snRNPs (Lund and Dahlberg, 1987) . Thus, variant forms of 
snRNPs which are developmentally regulated and/or tissue 
specific may facilitate differential splice-site selection. 
In addition to the above snRNPs, several other protein 
factors have to be shown to affect alternative splicing. One 
cellular factor isolated from mammalian cells termed ASF 
(alternative splicing factor) or SF2 has been found to affect 
the choice of alternative 5'-splice sites (Ge and Manley, 
1990; Krainer et al. 1990a). In vitro splicing studies with 
the early region of simian virus {SV40) involving the large T-
and small t-splice choices, and a model pre-mRNA substrate 
derived from the human p-globin gene, demonstrated that high 
concentrations of ASF / SF2 promote the use of proximal 5 ' -
splice sites, whereas low concentrations favor the use of 
distal 5'-splice sites. Recently, hnRNP Al has been reported 
to specifically counteract the effect of ASF/SF2 on the 
splice-site selection (Mayeda and Krainer, 1992). The hnRNP 
Al is not a general inhibitor of ASF/SF2, since both hnRNP Al 
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and ASF/SF2 are essential splicing factors (Krainer et al. 
1990b). However, when two alternative 5 1 splice sites are 
available for splicing, the ratio of hnRNP Al to ASF I SF2 
precisely determines which splice site is used in vitro. High 
concentrations of ASF/SF2 activates proximal 5' splice sites, 
whereas high concentrations of hnRNP Al favor distal 5' splice 
sites with several model and natural alternatively spliced 
pre-mRNAs. The regulation of these antagonistic activities 
may play an important role in the tissue-specific and 
developmental control of gene expression by alternative 
splicing of pre-mRNA. 
RNA Secondary Structure Several authors have suggested 
that one way in which sequences other than the primary 
consensus sequences might influence splicing patterns is to 
alter the secondary structure within the precursor RNA and 
thereby alter the utilization of a splice site (Solnick, 1985; 
Eperon et al. 1988; d'Orval et al. 1991; Libri et al. 1991; 
Estes et al. 1992). The potential of secondary structure to 
affect splice-site selection was first demonstrated with 
artificially constructed transcripts. When an exon was put 
into the loop of a hairpin by inserting long inverted repeats 
into the adjoining introns, in vitro splicing apparatus 
generated a novel, "jump"-spliced RNA that had the flanking 
exons joined directly together, leaving out the exon in the 
loop. To a lesser extent, the hairpin caused the same 
alternative splice in vivo, in transfected Hela cells 
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(Solnick, 1985). The extent by which the exon within a stem-
loop structure was "skipped" was inversely proportional to the 
stability of the stem (Solnick and Lee, 1987; Eperon et al. 
1988). Recently, secondary structure in the chicken fJ-
tropomyosin pre-mRNA has been shown to play a role in the 
regulation of the alternative splicing of this message 
(d'Orval et al. 1991; Libri et al. 1991; Guo et al. 1991). 
The chicken {J-tropomyosin pre-mRNA is spliced in a tissue-
specif ic manner to yield mRNAs coding for different isoforms 
of this protein. Exons 6A and 6B are spliced in a mutually 
exclusive manner; exon 6B was included in skeletal muscle, 
whereas exon 6A was pref erred in all other tissues. The 
distal portion of the intron upstream of exon 6B was shown to 
form stable double-stranded regions with part of the intron 
downstream of exon 6B. This structure repressed splicing of 
exon 6B to 7 in a Hela cell extract. Derepression of splicing 
occurred on disruption of this structure and repression 
followed when the structure was reformed. Thus, cellular 
factors which either stabilize or melt secondary structure may 
regulate alternative splicing. 
E. Functional Effects of Alternative Splicing of Pre-mRNA 
The functional effects of alternative splicing of pre-
mRNA is a subject of considerable interest. Strong 
correlations have been made between alternative splicing and 
biological function. These cases highlight the importance of 
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alternative splicing as a posttranscriptional regulatory event 
which can quantitatively and qualitatively control gene 
expression. Alternative splicing in most cases gives rise to 
protein isoforms sharing some identical regions, and varying 
in some specific domains, thus allowing for the modulation of 
protein function, such as regulation of protein localization, 
modification of protein activity, and production of novel 
protein activities. Alternative splicing is also used to 
quantitatively regulate gene expression, by giving rise to 
prematurely truncated open reading frames, or by regulating 
mRNA stability or translational efficiency via variability in 
the untranslated regions. As a mechanism to regulate gene 
expression and generate protein diversity, alternative 
splicing has advantages over gene rearrangement and extensive 
multigene families. It allows for switches in protein 
isoforms without permanent changes in the cell genetic 
content, and without changes in transcriptional activity. 
Functional effects of alternative splicing are reviewed below. 
1. Protein Localization 
Regulated alternative RNA processing is often used to 
specify the localization of proteins. There are a number of 
cases of proteins which are either present within the cell or 
are secreted. For example, the actin filament-severing 
protein gelsolin exists as both a plasma protein and a 
cytoplasmic protein. The two mature proteins are identical 
except for an additional 25 amino acid residues at the its 
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amino terminus of the plasma isoform. The two isoforms are 
expressed from the same gene by the differential use of 
alternative promoters and alternative splicing of 5' exons 
that code for the extra 25 amino acids of the mature plasma 
protein and a 27 amino acid cleavable signal peptide that 
directs its initial translocation from the cytosol into the 
rough endoplasmic reticulum (Kwiatkowski et al. 1986). No 
functional differences have been detected between the 
intracellular and extracellular forms of gelsolin. 
Avian epidermal growth factor receptor is another example 
of a protein that utilizes alternative splicing to generate 
membrane-bound and secreted forms (Flickinger et al. 1992). 
Epidermal growth factor receptor is a 170 KDa transmembrane 
glycoprotein which is encoded by 12 Kb or 8.6 Kb transcripts. 
Recently, a small transcript (2. 6 Kb) was isolated. This 
transcript encodes a soluble, secreted and truncated receptor 
molecule that can act as an antagonist to inhibit full-length 
receptor function. Sequence analysis of corresponding cDNA 
and genomic DNA revealed that the 2. 6 Kb epidermal growth 
factor receptor transcript is produced by alternative 
splicing. The 3' end of this transcript diverged from the 
sequence of the extracellular ligand-binding domain of the 
full length receptor are a result of the utilization of an 
alternative polyadenylation signal between exons 12 and 13 of 
the full length receptor transcript. 
The gene for immunoglobulin µ (Igµ) heavy chain also 
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gives rise to membrane-bound and secreted forms by alternative 
splicing. The Igµ heavy chain is present in early B 
lymphocytes as a membrane-bound form. Upon B-cell maturation, 
following antigen stimulation, levels of the membrane-bound 
form progressively decrease while the production of a secreted 
pentameric form increases. This switch is acheived by the 
alternative use of 3 1 end exons; the early B-lymphocyte form 
codes for the hydrophobic membrane-binding segment {Alt et al. 
1980; Early et al. 1980; Rogers et al. 1980). These examples 
show that alterative splicing could regulate the distributions 
of a protein between subcellular compartments. The targeting 
of protein to different locations involves the use of leader 
sequences that are removed from the mature protein during or 
after transportation, or by the use of membrane targeting 
sequences which are modified by attachment of membrane 
anchoring substituents. The distribution of proteins to more 
than one cell compartment could thus be regulated by 
alternative splicing of such targeting sequences. 
2. Modulation of Protein Function 
Functionally distinct protein isof orms are often produced 
by alternative splicing. Generation of the protein isoforms 
with differing functions due to alternative splicing has been 
found for some transcription factors {Lillycrop and Latchman, 
1992; Morris et al. 1992), receptors (Mosley et al. 1989; 
Baumbach et al. 1989; Takaki et al. 1990; Johnson et al. 1991; 
Flickinger et al. 1992), ion channels (Schwarz et al. 1988; 
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Timpe et al. 1988) and enzymes (Imamura and Tanaka, 1982; 
Noguchi et al. 1986; Liang et al. 1991). 
The RNA encoding the octamer-binding transcriptional 
factor Oct-2 is alternatively spliced to yield multiple mRNAs 
encoding different isoforms of the protein. Isoforms Oct 2.4 
and 2.5 differ from the other forms, Oct 2.1, 2.2, and 2.3, at 
their carboxyl termini. When introduced into cells lacking 
endogenous Oct-2, various Oct-2 isoforms have different 
effects on octamer-containing promoters (Lillycrop and 
Latchman, 1992). The Oct 2.1, 2.2, and 2.3 forms stimulate 
all octamer-containing promoters. However, the Oct 2.4 and 
2.5 forms can repress some promoters and stimulate others, 
depending on the sequence of the octamer motif and its context 
within the promoter. Thus alternative splicing can generate 
different isoforms of the Oct-2 proteins with different 
effects on gene expression. Alternative splicing has also 
been observed to affect the transcription factor Pit-1 in a 
similar manner (Morris et al. 1992). 
Changes in receptor functions can be correlated with 
alternative splicing of epidermal growth factor receptor 
(Flickinger et al. 1992), fibroblast growth factor receptor 
(Johnson et al. 1990; Johnson et al. 1991), interleukin 
receptors (Mosley et al. 1989; Takaki et al. 1990) and growth 
hormone receptor pre-mRNAs (Baumbach et al. 1989). In these 
cases, alternatively spliced mRNAs encode the soluble, 
secreted or truncated receptors which often lack transmembrane 
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domains or cytoplasmic domains, but contain extracellular 
ligand binding domains and retain ligand binding abilities. 
One can speculate that the secreted receptors can act as 
reservoirs to regulate levels of extracellular ligands, or 
inhibitors to block ligand-mediated responses by preventing 
interaction of the ligands with membrane-bound forms of 
receptors. For instance, alternatively processed mRNA from 
the epidermal growth factor receptor gene encodes a soluble 
truncated form of the receptor that can inhibit the function 
of the membrane-bound receptor by blocking ligand-dependent 
cell transformation (Flickinger et al. 1992). 
Alternative splicing can also generate enzyme isoforms 
with differing enzymatic activities. Different glucokinase 
isoforms are produced by tissue-specific alternative RNA 
splicing in liver and pancreatic islet cells (Liang et al. 
1991). Ll is major glucokinase isoform found in liver, and Bl 
in islets. Ll and Bl differ from each other by 15 amino acids 
at the NH2 terminus due to occasional skipping of exon 1. The 
Km values of the Bl and Ll isoforms are similar, but the Vmax 
of the Bl isoform is 2. 8 fold higher than that of the Ll 
isoform. In addition, two minor glucokinase isoforms in 
liver and islet cells, L2 and B2, generated from mRNAs lacking 
51 nucleotides due to the use of an alternate splice acceptor 
site in the exon 4, lack glucose phosphorylating activity. 
These results suggest that the alternative splicing of the 
glucokinase pre-mRNA dramatically affect the enzyme activities 
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of the gene products. 
In a limited number of cases alternative RNA processing 
gives rise to mature products with totally different 
functions. Here the alternatively spliced region encodes the 
major active site of the product. This type of alternative 
splicing is used in the generation of a number of peptide 
hormones. The calcitonin gene produces both calcitonin and 
calcitonin gene-related peptide (CGRP) by alternative splicing 
and poly(A) addition site usage (Amara et al. 1982; Jonas et 
al. 1985). Exons 1-3 contain the 5 1 untranslated and common 
coding regions. Exon 4 contains the calci tonin coding 
sequence and a poly(A) addition site and is used in thyroid. 
In brain and other neuronal tissue exon 3 is spliced to exons 
5 and 6, which contain the CGRP coding region and its 3 ' 
untranslated sequences and poly(A) addition site. Translation 
of these two different mRNAs produces two prehormones; 
proteolytic cleavages release the two different polypeptides, 
calcitonin and CGRP. Calcitonin functions in calcium 
retention while CGRP may have neuromodulatory activity 
(Fontaine et al. 1987). 
3. Effects on RNA Stability and Translatability 
Many genes produce transcripts with heterogeneity within 
the 5 1 and 3'-UTRs. The untranslated sequences are known to 
be involved in regulating translational efficiency (Kozak, 
199la,b) and RNA stability (Brawerman, 1987). Thus, 
alternative processing involving untranslated regions provides 
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the potential for regulated expression of the same gene 
product in different cells, or for regulating the expression 
of different products arising from alternative splicing of 
coding regions. A specific sequence promoting mRNA decay has 
been identified in the 3' noncodinq region. Shaw and Kamen 
(1986) have shown that the colony-stimulating factor-1 (CSF-1) 
gene produced two transcripts that were identical in the 
coding region but differed only in the 3 1 -UTR. One 3 1 -UTR 
contains a repetitive AUUUA element found in a number of 
rapidly turning over mRNAs, and causes a dramatic 
destabilizing effect when inserted into the 3 '-UTR of (j-globin 
mRNA. This suggests that CSF-1 expression can be regulated at 
the level of mRNA turnover according to the selection of 
different 3 1 untranslated sequences. 
The 5 1 -UTR has been shown to be involved in the 
regulation of translational efficiency. Many reports 
indicated that changes in the 5'-noncoding sequence of 
messages can make translation more or less difficult. The 
suspicion that complicated leader sequence can impair 
translation for mRNAs containing alternative 5'-UTRs has been 
confirmed for some gene transcripts, such as human complement 
protein C2 (Horiuchi et al. 1990), murine tissue inhibitor of 
metalloproteinases (Waterhouse et al. 1990) and rat insulin-
like growth factor I (Lowe et al. 1987; Foyt et al. 1991). 
Features of the 5 'UTRs which can influence translational 
capacity of the message include: 1) length; 2) the presence of 
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additional upstream open reading frames; and 3) the presence 
of secondary structure. 
CHAPTER III 
METHODS 
A. Materials 
Enzymes and chemicals were purchased from BRL 
(Gaithersburg, MD), Promega (Medison, WI), United States 
Biochemicals (Cleveland, OH) and Sigma (St. Louis, MO). [a-
32P]dCTP (specific activity 3,000 Ci/mmole), [a-32P]UTP 
(specific activity 400 Ci/mmole) and [35S]L-methionine 
(specific activity 1,000 Ci/mmole) were purchased from ICN 
Biochemicals (Costa Mesa, CA). Nytran filters were from 
Schleicher & Schull (Keene, NH) • N•-Benzyloxycarbonyl-L-
arginyl-L-argine 7- amido-4-methylcoumarin (Z-Arg-Arg-AMC) was 
from BACHEM Bioscience Inc. (Philadelphia, PA). 
Plasmids phCB79-2 (Chan et al. 1986) and phCB96-2 were 
gifts from Ors. S.J. Chan and D.F .. steiner (University of 
Chicago, Chicago, IL). The plasmid phCB79-2 (Figure 2) 
harbors the cDNA for a 2.3 Kb form of human cathepsin B mRNA 
containing 237 nt 5 1 -untranslated region (UTR), the coding 
region for preprocathepsin B, and a 798 nt 3 '-UTR, cloned into 
the EcoRI site of plasmid pGEM-2 (Promega). Adjacent to the 
cathepsin B cDNA is an SP6 promoter to drive mRNA synthesis 
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Figure 2: Human cathepsin B cDNAs in plasmids phCB79-2 and 
phCB96-2. The 5' and 3' UTRs, and coding region for the 
prepeptide, activation propeptide and mature enzyme in the 
cathepsin B cDNAs are indicated. Also shown are restriction 
sites. Panel A shows plasmid phCB79-2 and its cathepsin B 
cDNA insert. Panel B shows plasmid phCB96-2 and its cathepsin 
B cDNA insert. The cDNA insert in phCB96-2 is missing an 88 
nt segment (exon 2) present in phCB79-2. 
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and a T7 promoter to drive antisense or cRNA synthesis. A 
single internal EcoRI site interrupts the codon for glycine 
328 near the carboxyl-terminus of cathepsin B. Plasmid 
phCB96-2 (Figure 2) contains a human cathepsin B cDNA which is 
missing an internal 88 nt segment (exon 2) in the 5'-UTR of 
phCB79-2, and is bounded at its 3'-end by the same internal 
EcoRI site of phCB79-2 which interrupts the glycine 328 codon. 
This cDNA fragment is cloned into the EcoRI site of the 
plasmid pGEM-4Z. Positioned at each end of the insert are SP6 
and T7 promoters to drive mRNA and cRNA synthesis 
respectively. 
B. Solutions 
LB Broth: 10 g peptone (Giboco BRL), 5 g yeast extract 
(Gibco BRL), 6 g NaCl per liter 
SSPE: 10 mM NaH2P04, 0.15 M NaCl, 1.0 mM EDTA, pH 7.4 
TBE: 89 mM Tris-borate, 89 mM boric acid, 2 mM EDTA 
ssc: 15 mM sodium citrate, 0.15 M NaCl, pH 7.0 
TE: 10 mM Tris-HCl, 1 mM EDTA, pH 7.6 
DEPC-Trea ted H.zO: water was treated with 0.1% 
diethylpyrocarbobate for at least 12 hours and autoclaved. 
Pl Buffer: 100 µg/mi RNase A (Sigma), 50 mM Tris-HCl, 10 
mM EDTA, pH 8.0 
P2 Buffer: 200 mN NaOH, 1% sos 
P3 Buffer: 2.55 M KAc, pH 4.8 
QBT Buffer: 750 mM NaCl, 50 mM MOPS, 15% ethanol, 0.15% 
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Triton X-100, pH 7.0 
QC Buffer: 1.0 M NaCl, 50 mM MOPS, 15% ethanol, pH 7.0 
QP Buffer: 1.25 M NaCl, 50 mM MOPS, 15% ethanol, pH 8.2 
c. Cell Culture 
Tumor cells used in these studies included a cultured 
human colon carcinoma (from L.C. Erickson, Loyola University 
of Chicago, stritch School of Medicine), human melanomas A375P 
and A375M (from I.J. Fidler, Anderson Hosp. and Tumor Inst.), 
and human prostate carcinomas PC3P and PC3M (from J. 
Kozlowski, Dept. of Urology, Northwestern Med. Sch.). The 
variant A375M and PC3M were derived from the parental lines 
A375 (A375P) and PC3 (PC3P) respectively by culturing cells 
derived from experimentally produced metastatic lung tumor 
nodules. The variants A375M and PC3M were more metastatic 
than the parent cells after i. v. injection (experimental 
metastasis) and after s.c. transplantation (spontaneous 
metastasis) into young nude mice (Kozlowski et al. 1984). The 
melanomas A375P and A375M were cultured in Minimum Essential 
Medium supplemented with Earle's salts, essential amino acids, 
vitamins, sodium pyruvate (110 mg/L), penicillin (100 
units/ml), streptomycin (100 µg/ml), sodium bicarbonate (2.2 
g/L), and fetal bovine serum {10%). The prostate carcinomas 
PC3P and PC3M, and colon carcinoma were cultured in RPM! 1640 
supplemented with penicillin (100 units/ml), streptomycin (100 
µg/ml) and fetal bovine serum (10%). 70-80% confluent cells 
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were subcultured by scraping into 10 ml of serum free media, 
pelleting at 500xg and resuspending in fresh media containing 
10% fetal bovine serum. The media were changed three times 
weekly. 
D. Human Tissues 
Normal human kidney, spleen, liver, colon and breast 
tissues, and samples of several solid tumors were provided by 
the Cooperative Human Tissue Network and the National Disease 
Research Interchange. The tissues were reported to have been 
snap frozen at the time of collection and stored at -70°C. 
Pathological reports were provided for each tumor specimen. 
E. Total RNA Isolation 
Total RNAs were prepared from normal human tissues and 
solid tumors, and from cultured cells with a method described 
by Chomczynski and Sacchi (1987). Briefly, the cell pellet or 
tissue was crushed in liquid nitrogen and homogenized in 
denaturing solution containing 4M guanidinium thiocyanate, 25 
mM sodium citrate, pH 7.0, 0.5% sarcosyl, and 0.1 M 2-
mercaptoethanol. Sequentially, 0.1 volume of 2.0 M sodium 
acetate, pH 4.0, 1 volume of phenol, and 0.2 volume of 
chloroform-isoamyl alcohol mixture (49:1) were added to the 
homogenate. The aqueous phase was collected by centrifugation 
and the RNA in the aqueous phase was precipitated with an 
equal volume of isopropanol and washed with 70% ethanol. The 
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RNA was redissolved in diethyl pyrocarbonate (DEPC)-treated 
water and its integrity was examined by electrophoresis in an 
agarose gel (Fourney et al. 1988). 
F. Quantification of Catbepsin B mRNA 
The RNA dot blot procedure was used to quantify cathepsin 
B mRNA. Total RNA from normal human tissues and tumor cells 
were dissolved in a denaturing solution (50% formamide and lOx 
SSC) and heated at 65°C for 15 min. Varying amounts (0.1 µg 
to 10 µg) of denatured RNA were spotted onto Nytran filters. 
For a cDNA probe phCB79-2 was digested with EcoRI, and was 
fractionated by electrophoresis in 0.7% agarose gel. The DNA 
fragment containing human cathepsin B sequence was eluted from 
the gel slice by centrifugation through a 1. 5 ml polypropylene 
tube which had a hole at bottom and a small amount of glass 
wool as a cushion. The collected DNA was then extracted with 
1 volume of phenol/chloroform and precipitated by ethanol. 
The DNA pellet was redissolved in the TE buffer. The 
approximate concentration of the purified DNA fragment was 
determined by agarose gel electrophoresis and comparison to 
known amounts of DNA standards. The purified fragment was 
labeled with 32P-dCTP by the random primer labeling method 
according the Protocols and Applications Guide provided by 
Promega. Twenty ng of the DNA fragment in 30 µl of water was 
heated at 100°c for 3 min, and chilled on ice for 5 min. 
After addition of 10 µl of 5X labeling buffer, 2 µl of a 
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mixture of the unlabeled dNTPs (500 mM each of dATP, dTTP, 
dGTP), 2µ1 of acetylated BSA (10 mg/ml), 5 µ.l of (a-32P]dCTP 
(3, 000 Ci/mmole, 10 mCi/ml) and 5 units of Klenow enzyme 
(Promega), the mixture was incubated at room temperature for 
1 hour. The reaction was then terminated by heating at 100°C 
for 3 min and chilling on ice for 5 min. After addition of 2 
µl of 0.5 M disodium ethylenediamine tetraacetate (EDTA) and 
48 µl of water, the labeled DNA fragment was separated from 
unincorporated (a-32P]dCTP by a Shephadex G-50 spun-column 
chromatography (Maniatis et al. 1987). The purified labeled 
probe was used in hybridization. 
The Nytran filter was prehybridized for 4 hours in a 
solution containing 50% formamide, 5X Denhardt' s solution 
(Maniatis et al. 1987), 0.25 mg/ml of denatured salmon sperm 
DNA, 1.0% sos, 1.0 M NaCl, 10 mM Na2HP04 and 0.1% tetrasodium 
pyrophosphate. Hybridization was done at 42°C overnight in a 
fresh mixture of the same solution to which 32P-labeled human 
cathepsin B cDNA was added. After hybridization, the filter 
was washed three times (30 min each time) in 0.2x SSC and 0.5% 
SOS at 65°C, and exposed to Kodak XAR film. To rehybridize 
the blot, the cathepsin B probe was removed by washing the 
filter three times in O.OlX SSPE and 0.5% sos at 95°C for 30 
min. For the internal standard control, the stripped filter 
was similarly hybridized with 32P-labeled cDNA corresponding to 
the chicken 18s rRNA. 
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G. Northern Blot Analysis 
Total RNAs were denatured with formamide and 
formaldehyde and subjected to electrophoresis in a 1.1% 
agarose/0.02% formaldehyde gel in 3-[N-morpholino] 
propanesulfonic acid (MOPS) buffer (0.02 M MOPS, 5.0 mM sodium 
acetate, 1.0 mM EDTA, pH 7.0) (Fourney et al. 1988). The RNAs 
were transferred to Nytran filter, and the filter was 
hybridized as described above. 
H. RNase Protection Assay 
Protection assays were performed using a modification of 
a described method (Lowe et al. 1987). The RNase protection 
assay, outlined in Figure 3, depends on the production of a 
complementary RNA probe of high specific radioactivity which 
hybridizes to homologous sequences in mRNA. The resulting 
regions of double strand RNA are resistant to digestion by 
RNase T1 and RNase A. Single stranded regions in the labeled 
RNA probe which do not complement the message are degraded. 
Labeled RNA fragments of characteristic size are produced 
which correspond to specific mRNA species present in the 
sample. These labeled fragments can be analyzed for size by 
electrophoresis in a denaturing gel. 
For construction of the riboprobe vector, a 445-bp 
EcoRI/HindIII cDNA insert, containing sequence corresponding 
to the entire 5 1 -untranslated region of the human cathepsin B 
mRNA (Figure 4), was isolated from phCB79-2, and ligated into 
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Figure 3. Scheme for RNase protection assay. A DNA fragment 
containing 5'-end of human cathepsin B cDNA was cloned into 
pGEM-2. A radioactive antisense RNA probe was synthesized 
using T7 RNA polymerase and [a-32P]UTP as described in methods. 
The resulting antisense RNA was purified and then incubated 
with total RNA for annealing. RNase A and RNase Tl was added 
to digest single strand RNA. The protected double stranded 
fragments were analyzed by electrophoresis on a denaturing 
gel. 
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Figure 4: The riboprobe for RNase protection assay. The organization of a human 
cathepsin B mRNA, and the sizes of first six exons are shown. A 445 nt antisense RNA 
(riboprobe), complementary to the sequence from exon 1 to the middle of exon 5 of the 
cathepsin B mRNA, was synthesized for the RNase protection assay outlined in 
Figure 3. 
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a pGEM-2 vector {Promega) previously cut with EcoRI/HindIII. 
After linearizing the plasmid with EcoRI, the human cathepsin 
B riboprobe was synthesized in 20 µl reaction mixture 
containing 1.5 µg DNA template, 40 mM Tris-HCl {pH 7.5), 6 mM 
MgC12 , 10 mM NaCl, 2 mM spermidine, 10 mM dithiothreitol, 40 
units RNasin, 50 mM each of CTP, ATP and GTP, 20 µM UTP, 5 µM 
32P-UTP (50 µCi, 400 Ci/mmole), and 20 units T7 RNA polymerase 
according the Protocols and Application Guide provided by 
Promega. The mixture was then incubated at room temperature 
for 2 hours. After transcription, 1 µg of DNase I (BRL) and 
1 µl of 200 mM vanadyl-ribonucleoside complex (BRL) were 
added, and the mixture was incubated for 15 min at 37°C. The 
mixture was then extracted with O. 5 vol of phenol and 1 vol of 
chloroform and subjected to purification by a polyacrylamide 
gel electrophoresis. After running the 8% polyacrylamide/8 M 
urea denaturing gel, the 445-base riboprobe was located by 
autoradiography and eluted from a gel slice in 400 µl buffer 
(2 M ammonium acetate, 1% SOS and 25 µg/ml tRNA). The labeled 
riboprobe was precipitated with 2 volume of 100% ethanol, 
dried in vacuum and resuspended in DEPC treated water. 
The RNAs used in the assays were precipitated from 0.5 
M NaCl with 2 volume of ethanol, recovered by centrifugation, 
and dried in vacuum. 20 µg of total RNA was resuspended in 
29.5 µl of hybridization buffer (20 mM Tris-HCl, pH 7.6, 1 mM 
EDTA, 0.4 M NaCl, 0.1% sos, and 75% deionized formamide) to 
which O. 5 µl of H20 containing 500, 000-700, 000 cpm of the 
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labeled riboprobe was added. The mixture was heated to 85°C 
for 5 min and incubated at 45°C for about 16 hr. After 
hybridization, 270 µl of RNase digestion buffer (10 mM Tris-
HCl, pH 7.6, 5 mM EDTA, 300 mM NaCl, 40 µg of RNase A per ml 
(Sigma), and 2 µg of RNase Tl per ml (BRL)) was added, and the 
mixture was incubated for 1 hr at 30°C. SDS was then added to 
a final concentration of 0.6% followed by addition 50 µg of 
proteinase K. The mixture was incubated at 37°C for 15 min, 
and then extracted with 0.5 volume of phenol and 1 volume of 
chloroform. Twenty µg of tRNA and 2 volume of ethanol were 
added to the aqueous layer. After 30 min at -20°c, the 
precipitate was collected by centrifugation, dried, and 
resuspended in formamide sample buffer (80% deionized 
formamide and o. 2% of bromophenol blue) . The sample was 
heated to 95°C for 3 min, chilled on ice, and applied to an 8% 
polyacrylamide/8 Murea denaturing gel. After electrophoresis 
at 50°C in 0.5x TBE, the gel was dried and exposed to Kodak 
XAR film at -70°C overnight. RNA bands, corresponding to the 
alternative 5 '-UTRs were quantitated by densitometry, and 
their sizes estimated by comparing their mobilities with those 
of DNA markers. 
I. Polymerase Chain Reaction (PCR) Amplification of cDNA 
The first strand cDNA was synthesized with the 
Superscript™ RNase H- Reverse Transcriptase (BRL) from total 
RNA using random primers according the method described by 
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Kawasaki (1991). The reaction mixture contained 1 µg total 
RNA, 100 pmole of random primer mixture (Pharmacia, Alameda, 
CA), 40 units RNasin, 1.0 mM each of dCTP, dATP, dCTP and 
dGTP, and 200 units of Superscript™ RNase H" Reverse 
Transcriptase in a final volume 20 µl. Then the mixture was 
incubated at room temperature for 10 min and at 42°C for 1 
hour. Four µl of this reaction mixture was used directly as 
template for PCR. To amplify the 5 1 region of cathepsin B 
cDNA, PCR was performed with a pair of specific 
oligonucleotide primers having the HindIII and EcoRI 
restriction sites at their termini to facilitate subcloning; 
the primers were 5 1 GGGGATCCAACCGCTCCGCTGCGCGC (sense) in exon 
1, and 5 1 GGGAATTCGGTGTGGATGCAGATCCG (anti sense) in exon 5 
(Figure 5). The resulting fragment was subcloned into the 
HindIII/EcoRI site of the pBluescrip vector (Stratagene, La 
Jolla, CA) to give phCBel.4. For amplifying the cathepsin B 
cDNA missing exons 2 and 3, the sense primer, 
5'CAGCGCTGGGCCGGGCAC, was complementary to 9 nucleotides on 
each side of the exon 1-exon 4 junction, and the antisense 
primer was 5 'CCAGGACTGGCACGACAGGC and complementary to a 
sequence present in the flanking 3' untranslated region of all 
known, full length cathepsin B mRNAs (Figure 6). The reaction 
mixture contained 4 µl of the template solution (see above), 
2.5 units of Tag polymerase (United States Biochemicals), 400 
nM of each primer, 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM 
MgC12 , 0.1 mg/ml gelatin, 0.01% Tween 20 and 0.01% NP-40 in a 
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Figure 5. Scheme for PCR amplification of 5' -end of cathepsin 
B cDNA. Alternatively spliced forms of human cathepsin B mRNA 
are shown. The 5' (sense) and 3' (antisense) primers used in 
PCR were complementary to the indicated regions in exons 1 and 
5 respectively. PCR products of 549 bp, 461 bp and 306 bp are 
expected after amplification of the cDNAs containing the full 
length 5' UTR, those missing exon 2, and those missing exons 
2 and 3, respectively. 
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Figure 6. Scheme for the PCR amplification of cathepsin B 
cDNA missing exons 2 and 3. Three cathepsin B transcripts 
which result from alternative splicing in their S' regions are 
shown. The cDNA for the transcript lacking exon 2 and 3 was 
amplified with a sense primer which is complementary to the 
sequence of the exon 1-exon 4 junction, and an antisense 
primer which is complementary to the sequence in the exon 11 
(3'-untranslated region). A 934 bp PCR product is expected. 
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final volume 100 µl. Cycling was performed in a Eppendorf DNA 
thermal cycler with a profile of 30 sec at 95°C, 1 min at 
65°C, and 2 min at 72°C for 30 cycles. Ten µl of the reaction 
product were analyzed by agarose gel electrophoresis, 
transferred onto a Nytran filter, and the filter hybridized 
with 32P-labeled human cathepsin B cDNA. 
J. sequencing of PCR Fragments 
PCR reaction products were isolated, digested with 
HindIII and EcoRI and subcloned into the pBluescript vector 
for single strand sequencing by the dideoxy chain termination 
method (Sanger et al. 1977). 
The single strand DNA was prepared with the method 
described by Russel et al (1986). The HBlOl[F+] cells 
containing phCBel.4 plasmid were patched onto LB plates 
containing 100 µg ampicillin/ml and incubated overnight at 
37°C. A portion of each patch was used to inoculate 1.5 ml 
modified LB broth (16 g tryptone, 10 g yeast extract, 5 g NaCl 
per liter) plus glucose (0.1%) and 100 µg ampicillin/ml in a 
culture tube, giving visible turbidity to the solution. 
5x109-1010 of helper phage R408 (Promega) were added. 
Next 
The 
cultures were incubated at 37°C with vigorous agitation for 4-
5 h. After centrifuging the infected culture, the 1.3 ml of 
the supernatant was transferred to a tube containing 0.2 ml of 
2. 5 M NaCl and 20% polyethyleneglyco-6000 (PEG-6000) and 
incubated at room temperature for 15 min. The mixture was 
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then centrifuged in a microfuge for 5 min at room temperature. 
The supernatant was removed by aspiration, and the tube was 
briefly recentrifuged to remove the remaining trace of liquid. 
The pellet was resuspended in 100 µl of 10 mM Tris-HCl, pH 
8.0, containing 2mM EDTA, and extracted with 50 µl of phenol. 
The aqueous phase was collected by centrifugation, and the 
single strand DNA in the aqueous phase was precipitated with 
250 µl of a 25:1 mixture of ethanol and 3 M sodium acetate, 
washed with absolute ethanol, dried at 65°C for 10 min and 
dissolved in 20 µl of TE solution. The single strand DNA was 
then sequenced with Sequenase Version 2. o (United States 
Biochemicals) according the manufacturer's instruction. 
K. construction of Expression Vectors 
SP6/cathepsin B mRNA expression vectors were made by 
inserting cathepsin B cDNA into pGEM2 (Promega) vector 
adjacent to the SP6 promoter, using standard cloning 
procedures. The insert and vector DNAs were prepared by 
restriction enzyme digestion (Maniatis et al, 1987). Each 
digestion mixture contained 5 µg of plasmid DNA, 5 µl of 
appropriate restriction lOx buffer, 10-25 units of appropriate 
restriction enzyme in final volume of 50 µl. The mixture was 
incubated at 37°C for 1-3 h. The reaction end point was 
verified by electrophoresis of an aliquot of the sample on an 
agarose gel. After restriction enzyme digestion, the vectors 
and inserts were separated by agarose gel electrophoresis, and 
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the DNA fragments were eluted from the agarose gel by 
centrifugation (see above). The vector and insert were then 
ligated overnight at 14°C with 1 unit of T4 ligase (BRL) in 
the assay buffer provided by the manufacturer. The ligated 
DNA was transformed in E.coli strain HBlOl. Ampicillin 
resistant clones were selected, plasmid was prepared, and 
samples were analyzed by restriction digestion. 
The construction of phCB79-2-2 is outlined in Figure 7. 
It contains the shorter 5 1 -UTR lacking exon 2 from phCB96-2, 
the entire preprocathepsin B coding sequence, and the shorter 
3 '-UTR from plasmid phCB79-2. Briefly, a 357 bp EcoRI/HindIII 
fragment from phCB96-2, containing exons 1, 3, 4 and part of 
exon 5, was inserted into EcoRI/HindIII site of pGEM-2 vector 
(Promega) to make plasmid phCBel. 3. 4. 5. phCB79-2-2 was 
constructed by replacing a sequence from NheI site to ApaI 
site of phCB79-2 with 593 bp NheI/ ApaI fragment from 
phCBel.3.4.5. phCB79-2-2,3 is identical to phCB79-2-2 except 
that it is also missing exon 3. Its preparation is described 
in Figure 8. A 87 bp Eco47III/ApaI fragment from phCBel.4, 
containing part of exon 1 and part of exon 4, was used to 
replace the corresponding sequence from the Eco47III to the 
ApaI site in the phCB96-2 to make phCB96-2-3. A 206 bp 
EcoRI/HindIII fragment from phCB96-2-3 was isolated and 
inserted into the EcoRI/HindIII site of pGEM-2, to give 
phCBel.4.5. Then phCB79-2-2.3 was constructed by replacing 
the sequence from the NheI site to the ApaI site of phCB79-2 
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EcoRI 
phCB96-2 Eco RI pGEM-2 
Nhel EcoRI 
Hind Ill 
phCBe1 .3.4.5 
EcoRI 
Eco RI 
J<el/Apal 
Nhel 
Figure 7. Scheme for the construction of plasmid phCB79-2-2. 
phCB79-2-2, containing a cathepsin B cDNA lacking exon 2, was 
constructed from phCB96-2 and phCB79-2 in two steps. First, 
a 357 bp fragment from phCB96-2 was excised with EcoRI and 
HindIII, and ligated into the EcoRI/HindIII sites of a pGEM-2 
vector to make phCBel. 3. 4. 5. To make phCB79-2-2 a 593 bp 
fragment was removed from phCBel.3.4.5 with NheI and ApaI and 
ligated into the corresponding NheI/ApaI site of phCB79-2. 
Restriction enzymes used for subcloning in each step are 
indicated. The cathepsin B cDNA fragment in each vector is 
shown by double lines. Also shown are restriction sites in 
each vector. 
61 
Figure 8. Scheme for the construction of plasmid phCB79-2-2. 3 
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Figure 8. Scheme for the construction of plasmid phCB79-2-
2.3. phCB79-2-2.3, containing cathepsin B cDNA lacking exons 
2 and 3 was constructed from phCBel.4, phCB96-2 and phCB72-2 
in three steps. First, an 87 bp fragment from phCBel.4 was 
removed with Eco47III and Apa!, and ligated into the 
Eco47III/ApaI site of phCB96-2 in place of a corresponding 
region to make phCB96-2-3. Second, a 206 bp EcoRI/HindIII 
fragment from phCB96-2-3 was ligated into the EcoRI/HindIII 
sites of pGEM-2 vector to make phCBel.4.5. Finally, a 442 bp 
NheI/ApaI fragment from phCBel.4.5 was used to replace the 
corresponding NheI/ApaI segment of phCB79-2 to give phCB79-2-
2. 3. Restriction enzymes used for subcloning in each step are 
indicated. The cathepsin B cDNA fragment in each vector is 
shown by double lines. Also shown are restriction sites in 
each vector. 
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with the 442 bp NheI/ ApaI fragment from phCBel.4.5. 
L. In Vitro Transcription and Translation 
Plasmids were isolated by chromatography on QIAGEN 
columns (QIAGEN Inc., Chatsworth, CA) according to the 
manufacturer' s instruction. Two hundred ml of LB broth 
containing 100 µg ampicillin/ml was inoculated with E.coli 
transformed by the appropriate plasmid, and incubated at 37°C 
overnight with vigorous agitation. The cells were pelleted by 
centrifugation, resuspended in 4 ml of Pl buff er to which 4 ml 
of P2 buffer was added, and incubated at room temperature for 
5 min. After addition of 4 ml of P3 buffer, the mixture was 
centrifuged at 4°C for 30 min (15,000xg). The supernatant was 
then removed and applied onto a QIAGEN-tip 100 column, which 
was preequilibrated with 3 ml of QBT buffer. The column was 
next washed with 10 ml of QC buffer, and the plasmid DNA 
eluted with 5 ml of QF buffer. The collected DNA was 
precipitated with 0.7 volume of isopropanol, washed with 70% 
ethanol and dissolved in TE buffer. 
For in vitro transcription, the isolated plasmid DNA was 
linearized with XbaI, and purified by phenol-chloroform 
extraction and ethanol precipitation. Each transcription 
reaction contained 5 µg of the appropriate linearized vector, 
10 µl sx transcription buffer (Promega), 10 mM dithiothreitol, 
50 units RNasin, 0.5 mM each of ATP, CTP, and UTP, 0.05 mM 
m7G(5')ppp(5')G and 40 units of SP6 RNA polymerase in final 
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volume of 50 µl. To estimate RNA synthesis, a 3 µl aliquot of 
the complete reaction mixture was added to 10 µCi of dried [~-
32P]UTP prior to the start of the reaction. After incubation 
at 37°C for 1 hour, the transcripts were purified by phenol-
chloroform extraction and ethanol precipitation, dissolved in 
DEPC-treated water and stored at -20°c. After each 
purification step, portions of these samples were analyzed on 
a Northern blot to ensure that no loss or degradation of the 
RNA had occurred. Reaction mixtures containing radiolabeled 
UTP were treated with 10 µg of tRNA and 5% trichloroacetic 
acid, and the insoluble radioactivity measured with a Beckman 
LS7500 liquid scintillation spectrometer to determine the 
amount of RNA transcribed. 
For in vitro translation, 100 ng to 300 ng of capped mRNA 
was heated at 65°C for 15 min, added to a reaction mixture 
containing 35 µl of rabbit reticulocyte lysate, 40 units of 
RNasin ribonuclease inhibitor, an amino acid mixture {minus 
methionine) , o. 02 mM each, and 4 µl of [3ss )methionine 
{l,lOOCi/mmole) at 10 mCi/ml on a final volume of 50 µl. The 
reaction mixture was then incubated at 30°C for various times 
from 15 to 60 min. All samples were kept at 4°C before and 
immediately after translation. 
M. Analysis of the Translation Products 
Five µl samples from each translation mixture were 
diluted to 10 µl in an electrophoresis sample buff er 
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containing 0.125 M Tris-HCl (pH 6.8), 2% SDS, 2% 2-
mercaptoethanol, 20% glycerol and o. 001% bromphenol blue, 
boiled for 3 min, and electrophoresed on a 10% polyacrylamide 
sos gel in an electrode buffer (pH 8.3) which contained 0.025 
M Tris, 0.192 M glycine and 0.1% SDS (Laemmli, 1970). Gels 
containing the 35S-labeled translation products were dried and 
autoradiographed overnight at -70°C using an intensifying 
screen and Kodak XAR film (Laskey, 1980). 
To measure [ 35S]methionine incorporation, a 2 µl aliquot 
of each translation reaction was incubated in 250 µl of lN 
NaOH, 2% H20 2 at 37°C for 10 min. After addition of 1.0 ml of 
ice-cold 25% trichloroacetic acid/2% casamino acids, the 
samples were incubated on ice for 30 min. The precipitates 
were collected on Whatman GF/A filters by vacuum filtration, 
washed with 3 ml of 5% TCA three times and once with 2 ml of 
acetone, dried, and the radioactivity measured with a Beckman 
LS7500 liquid scintillation spectrometer. 
N. Folding of an In Vitro Translation Product 
Plasmid phCB79-2-2.3 was used as a template for 
preparation of m7G(5')ppp(5')G capped synthetic RNA as 
described above. The in vitro translation was described in the 
previous section, except that the reaction mixture contained 
0.6 µg of synthetic, capped mRNA and a complete mixture of 
amino acids (0.02 mM each) in a final volume of 109 µl. 
To promote folding of the translation product, the in 
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vitro translation mixture {109 µl) was dialyzed against buffer 
(0.05 M Tris-HCl, 20% glycerol, 0.1 mg/ml bovine serum 
albumin, o. 15 M NaCl, 1 mN di thiothrei tel, and O. 1 mM Na2EDTA) 
to which had been added 6.0 M guanidinium hydrochloride. At 
intervals of 10 minutes or 30 minutes the dialysis buffer was 
removed, diluted with an equal volume of buffer to reduce the 
guanidinium hydrochloride by half, and the dialysis continued 
for two additional cycles of dilution. The final cycle was 
followed by dialysis against buffer only (Hager and Burgess, 
1980; Vinson et al. 1988) • The samples were clarified by 
centrifugation at 14,000 x g for 15 min, quick frozen, and 
store at -20°c for later analysis. 
In an alternative procedure, some samples (108 µl) were 
treated with 12 µl of a lOX "oxide-shuffling" redox buffer ( lX 
contains O .15 M Tris-HCl, pH 8. o, 1 mM Na2EDTA, O. 3 mM 
glutathione disulfide, and 3. O mM reduced glutathione) and 
incubated at room temperature for 24 hours (Jaenicke and 
Rudolph). Sample were frozen and stored as described above. 
These procedures are summarized in Figure 9. 
o. Measurement of cathepsin B Activity 
Cathepsin B activity was measured using the fluorogenic 
substrate N•-Benzyloxycarbonyl-L-arginyl-L-argine 7- amido-4-
methylcoumarin (Z-Arg-Arg-AMC) (Achkar et al. 1990). The 
enzyme was converted to its free thiol form by preincubation 
with dithiothretol and EDTA. A 50 µl sample was incubated 
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addition of 1 OX "oxido 
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(1 X contains 0.3 mM 
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Figure 9. Procedure for folding of translation products in 
vitro. In vitro translated products were treated in one of 
two ways to promote proper folding: with an "oxide-shuffling" 
buffer to facilitate disulfide bond formation; and with 
decreasing concentration of guanidinium hydrochloride with 
changes at 10 and 30 min intervals. 
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with an equal volume of activation buffer containing 30 mM 
dithiothretol and 15 mM EDTA, pH 5.2, for 30 min at 25°C. 
Then 37.5 µ1 of 0.6 M citrate/phosphate buffer, pH 6.2 was 
added, and the reaction was initiated by the addition of 12 . 5 
µl of the substrate (1.128 mM in dimethyl sulfoxide (DMSO)) at 
a final concentration of 94 µ.M and 8. 3% DMSO. The AMC product 
was quantitated with an SLM/Aminco SPF-500C spectrofluorometer 
at excitation and emission wavelengths of 370 and 460 nm, 
respectively. Some samples were also pretreated for 30 min at 
37°C with pepsin (0.83 mg/ml) to remove the remainder of the 
activation propeptide prior to assay (Achkar et al. 1990; 
Rowan et al. 1992). 
CHAPTER :IV 
RESULTS 
A. ouantif ication of Total Cathepsin B mRNA in Human Normal 
Tissues and Tumors by Slot Blot Analysis 
Cathepsin B mRNA in different normal human tissues and 
human tumors was quantified by hybridization of RNA slot blots 
with labeled human cathepsin B cDNA from phCB79-2 as the 
probe. Total RNAs were isolated from five kinds of normal 
human tissues, skeletal muscle, kidney, liver, spleen and 
colon, and from two cultured human melanoma cells, A375P and 
A375M {Chomezynski and Sacchi, 1987) . Agarose gel 
electrophoresis of the total RNAs was performed following 
denaturation with formamide and formaldehyde. The integrity 
of the 18S and 28S ribosomal RNA indicated that the isolated 
RNAs were largely intact. 
Figure lOA shows a representative slot blot result for 
cathepsin B mRNA in five normal human tissues and two melanoma 
cells. The specificity of the cDNA probe was verified by a 
Northern blot (Figure 11), which shows that the probe only 
hybridized to cathepsin B mRNAs. Cathepsin B mRNA levels in 
A375 melanoma variants are higher than those in all the normal 
tissues examined. A375M, which is highly metastatic,·shows a 
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Figure 10. Slot blot hybridization analysis of human normal 
tissues and cultured melanoma cells for levels of cathepsin B 
mRNA 
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colon 
skeletal muscle 
kidney 
spleen 
breast 
liver 
A375M 
A375P : 
B colon 
skeletal muscle 
kidney 
spleen · 
breast , 
liver 
A375M 
A375P 
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Figure 10. Slot blot hybridization analysis of human normal 
tissues and cultured melanoma cells for levels of cathepsin B 
mRNA. Panel A, Total RNAs were isolated from normal human 
tissues, skeletal muscle, kidney, liver, spleen and colon, and 
two cultured human melanoma cells, A375P and A375M. 10 µg, 1 
µg or 0.1 µg of total RNA was loaded onto Nytran filter, and 
the filer was hybridized with 32P-labeled human cathepsin B 
cDNA. Panel B, To ensure equal loading of RNA in all the 
slots, the blot was stripped and rehybridized to a control 
probe, the 32P-labeled cDNA of chicken 18S RNA. 
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higher expression of cathepsin B mRNA than A375P which is 
poorly metastatic, even after adjustments for differences in 
loading. To ensure that similar amounts of RNAs were present 
in each sample, the filter was stripped of the cathepsin B 
cDNA probe, and was rehybridized to a cDNA probe for the 
chicken 18S rRNA {Figure lOB). Intensities of the 
hybridization signals were measured by densitometry. 
Table 1 shows the relative levels of cathepsin B mRNAs in 
five normal tissues and two cultured melanoma cells normalized 
to the levels of 18S rRNA. Compared to the spleen, which has 
the highest level of cathepsin B mRNA among the five normal 
tissues examined, the cathepsin B mRNA levels in A375P and 
A375M were 1.5 and 2.3 fold higher respectively. 
B. Quantification of Variant Cathepsin B mRNAs by Northern 
Blot and RNase Protection Assay 
Cathepsin B mRNAs are heterogeneous due to differences in 
processing of 5'- and 3'-ends of the pre-mRNA (Gong et al. 
1993). The variable use of a cryptic 5' splice site in exon 
11 with splicing to exon 12 causes the occasional loss of a 
polyadenylation signal in exon 11 and results in messages 
which differ by about 2 Kb in the lengths of their 3'-UTR. 
Variable removal of exon 2 produces messages which differ by 
88 nt in their 5'-UTR. The discovery of multiple cathepsin B 
mRNAs generated by the alternative processing of the pre-mRNA 
opens up the possibility that it may be a mechanism for 
regulating cathepsin B expression in human tissues. 
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Table 1. Relative level of cathepsin B mRNA in human tissues 
and tumor cells 
Normal Tissues 
Colon 
Breast 
Skeletal Muscle 
Liver 
Spleen 
Kidney 
Cultured Melanomas 
A375P, poorly metastatic 
A375M, highly metastatic 
Ratio of density 
(CB/18s RNA) 
0.01 
0.21 
0.15 
0.18 
0.30 
0.25 
0.46 
0.68 
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To investigate alterative splicing of the 3'-UTR, 
Northern blot analysis was performed. Figure 11 is a 
representative blot which reveals the presence of the 2.3 Kb 
and 4. O Kb transcripts in normal human skeletal muscle, 
kidney, liver, spleen and colon, and in the two human melanoma 
variants, A375P and A375M. Densitometric scan of the Northern 
blot (Table 2) revealed that the ratio of the 2. 3 Kb 
transcript to the 4.0 Kb transcript only varied by about a 
factor 2, from 2.8 to 6.2. These differences do not appear 
large enough to be suggest that variant 3'-UTRs in cathepsin 
B mRNA have a regulatory significace. 
An RNase protection assay was used to detect and quantify 
human cathepsin B mRNAs with differing 5'-ends. The riboprobe 
used is protected by the first 445 bases of mRNA containing 
the longer 5'-UTR (Figure 4). Based on the sequences of the 
two 5'-UTRs found in human cathepsin B cDNA (Chan et al. 1986; 
Gong et al. 1993), hybridization of this riboprobe with human 
cathepsin B transcripts should result in three protected 
fragments, a 445 nt fragment corresponding to mRNA containing 
the full length 5'-UTR, and 276 and 81 nt fragments 
corresponding mRNA lacking exon 2 . These fragments were 
separated on a denaturing gel, and their sizes were estimated 
by comparing their mobilities with those of ¢Xl74 RF 
DNA/HaeIII molecular size markers. These three bands were 
seen in Figure 12. The densities of the 276 nt bands were 
much higher than those of 445 nt bands in all tumor cells 
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4.0Kb 
2.3Kb 
Figure 11. Northern blot of cathepsin B mRNA from human 
normal tissues and cultured melanoma cells. Total RNAs were 
isolated from normal human tissues, skeletal muscle, kidney, 
liver, spleen and colon, and two cultured human melanoma 
cells, A375P and A375M. 15 µg of total RNA from each sample 
was denatured, electrophoresed on agarose gel and transferred 
onto Nytran filter, and the filter was hybridized with llp-
labeled human cathepsin B cDNA. The presence of 2.3 Kb and 
4.0 Kb transcripts are indicated. 
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Table 2. Relative proportion of 2.3 Kb and 4.0 Kb cathepsin 
B mRNAs 
Normal Tissues 
Skeletal muscle 
Kidney 
Liver 
Spleen 
Colon 
Cultured Tumors 
A375P, poorly metastatic 
A375M, highly metastatic 
2.3Kb/4.0Kb ratio• 
6.2 
2.8 
6.1 
3.5 
2.7 
5.1 
6.0 
* The signals of 2.3 Kb and 4.0 Kb bands from Northern blot 
were measured by densitometry. Ratios of the signals of these 
two bands were calculated. 
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examined, including five cultured tumor cells, A375M, A375P, 
PC3M, PC3P and colon carcinoma, and three solid tumors, two 
colon carcinomas (one a liver metastasis) and a breast cancer. 
The densities of these two bands were similar in most of 
normal tissues examined, such as liver, kidney, breast and 
colon. In contrast, in skeletal muscle the density of the 445 
nt band was higher than that of the 276 nt band. The ratio of 
the intensity of the 276 nt band to that of the 445 nt band is 
a measurement of the relative proportions of the two 
transcripts in human tissues and tumors (Table 3) . The ratios 
varied from less than 0.1 to 3.2 for normal tissues, and from 
6.0 to 20.1 for the tumors. From the results in Table 3, it 
can be seen that the transcripts lacking exon 2 are much more 
abundant in human tumors than in normal human tissues. Figure 
12 also reveals the presence of an unexpected fragment of 
about 140 nt which was found in significant amount in three 
solid tumors and two cultured human melanoma cells, A375M and 
A375P. This fragment arises from transcripts lacking exon 3 
(see below). When the RNase protection assay was performed 
with probe alone (without RNA), no protected bands were seen. 
When the RNase protection assay was performed without RNase 
digestion, only the 445 base fragment was seen (Figure 13). 
C. Amplification of the 5 1 -Ends of Cathepsin B cDNA from 
Human Normal Tissues and Tumors by PCR 
RNase protection studies revealed a fourth major 
protected band (140 +/- 10 bases) with mRNAs from human breast 
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Figure 12. RNase protection of variant 5' -ends of human 
cathepsin B mRNAs. After hybridization to total RNA, the 445 
nt riboprobe is completely protected from RNase digestion by 
transcripts which contain the complete 5'-UTR. Transcript 
lacking exon 2 produce 276 and 81 nt fragments. Panel A, RNA 
from normal tissues and two cultured melanoma cell lines. 
Panel B, RNA from three different human tumors, two colon 
carcinomas (one a liver metastasis) and breast cancer. Panel 
C, RNA from cultured human tumor cells. RNA from some human 
tumors give rise to a fourth prominent band (*) which _appears 
to be about 140 nt in length. This fragment arises from 
transcript missing exons 2 and 3. 
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Table 3. Relative proportion of cathepsin B mRNA transcripts 
with and without exon 2 
Normal Tissues 
Colon 
Breast 
Skeletal muscle 
Liver 
Spleen 
Kidney 
Solid Tumors 
Colon 
Colon (metastasis to liver) 
Breast 
Cultured Tumors 
A375P, poorly metastatic 
A375M, highly metastatic 
PC3P, poorly metastatic 
PC3M, highly metastatic 
Colon, unknown 
276/445 ratio* 
0.8 
2.4 
< 0.1 
2.6 
3.2 
2.3 
20.1 
18.6 
23.7 
6.0 
9.6 
8.9 
12.0 
14.4 
* The signals of 276 base and 445 nt bands from RNase 
protection assays were measured by autoradiography and 
densitometry. Ratios of the signal intensities were calculated 
after correcting for differences in the (a-32P]UMP content of 
each band. 
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Figure 13. Evaluation of the riboprobe used in the RNase 
protection assay. RNase protection assay was performed with 
probe alone (without RNA), no protected bands were seen. 
RNase protection assay was performed without RNase digestion, 
only 445 nt fragment was seen (Riboprobe) . 
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and colon carcinomas and human melanomas. One possibility was 
that this fragment originated from a cathepsin B transcript in 
which exon 1 was spliced directly to exon 4, deleting exons 2 
and 3 (125 base fragment expected in RNase protection assay). 
To test this, the 5 '-ends of the cathepsin B mRNAs from 
skeletal muscle, solid colon carcinoma, cultured tumor cells 
A375M and PC3M were reverse transcribed into cDNA and 
amplified by PCR. After electrophoresis, the PCR products 
were transferred onto a Nytran filter and hybridized with 
human cathepsin B cDNA. This hybridization revealed 549 bp 
and 461 bp fragments which were derived from cDNAs which 
contain or lack exon 2 (Figure 14) • The 4 61 bp band was 
predominant with RNA from the solid colon carcinoma and the 
cultured tumor cells, A375M and PC3PM, but was barely 
detectable with RNA from muscle. These results confirmed the 
findings obtained with the RNase protection assay. The 306 bp 
band is the expected product for cDNA lacking both exons 2 and 
3. In agreement with RNase protection studies, 306 bp band 
was seen with A375M and solid colon carcinoma, but not with 
skeletal muscle and PC3M. 
D. Molecular Cloning of Human cathepsin B cDNA Lacking Exons 
2 and 3 
In order to characterize the transcript lacking exons 2 
and 3, a cDNA corresponding to this transcript was cloned by 
PCR. Total RNA isolated from A375M cells was ·reverse 
transcribed and the single stranded cDNA was amplified by PCR. 
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Figure 14. PCR amplification of the 5'-ends of cathepsin B 
cDNA from human normal tissues and tumors. This figure shows 
a Southern blot of products obtained after reverse 
transcription and PCR amplification of the 5'-ends of 
cathepsin B cDNA from two human tumor cell lines, A375M 
(melanoma) and PC3P (prostate carcinoma) , a solid colon 
carcinoma, and normal skeletal muscle. The pair of primers 
used for the PCR were complementary to regions in exon 1 and 
exon 5. The 549 and 461 bp bands are from cDNAs which contain 
and lack exon 2 respectively. The 3 06 bp fragment is the 
expected product of cDNA which lacks both exons 2 and 3. The 
306 bp band was only seen with cDNAs from tissues which 
yielded detectable levels of the 140 nt band in RNase 
protection studies (Figure 12). 
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The primers used in PCR have the HindIII and EcoRI restriction 
sites at their termini, and were designed to amplify the 5'-
end of cathepsin B cDNA from exon 1 to the middle of exon 5 as 
described in the Methods. Because the level of cathepsin B 
cDNA missing exons 2 and 3 was low, the PCR products were 
separated by agarose gel electrophoresis, and fragments 
smaller than 461 bp were eluted and reamplified by PCR. 
Figure 15 shows the 306 bp product which has the expected size 
of a cathepsin B cDNA fragment containing exon 1, exon 4 and 
part of exon 5, and missing exons 2 and 3. This PCR fragment 
was cloned into the pBluescript vector (Stratagene) to make 
the plasmid phCBel. 4 for single strand sequencing. The 
complete sequencing of several positive clones confirmed that 
the 306 bp PCR product was derived from cathepsin B mRNA which 
lacked exons 2 and 3 • Figure 16 shows a portion of a 
representative sequence which contains an exon 1 - exon 4 
junction. In order to further characterize the transcript 
lacking exons 2 and 3, a fragment from phCBel.4, containing 
part of exon 1 and part of exon 4, was cloned into phCB79-2 to 
replace the corresponding region containing exons 2 and 3. 
The resulting plasmid, phCB79-2-2.3, harbored a cathepsin B 
cDNA lacking exons 2 and 3 as described in Methods (Figure 8) . 
E. Detection of Cathepsin B mRNA That Is Missing Exons 2 and 
3 by PCR 
Total RNA from tumor cells was used to clone a cathepsin 
B 5' cDNA fragment which is missing exon 2, noncoding, and 
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Figure 15. PCR amplification of 5'-end of cathepsin B cDNA 
missing exons 2 and 3. 5 1 -ends of cathepsin B cDNAs were 
amplified from A375M cells as described in Figure 15. 
Products smaller than 461 bp were isolated by agarose gel 
electrophoresis and used as templates for reamplif ication by 
PCR. A 306 bp fragment (indicated by arrow) was obtained, 
which is expected product of cathepsin B cDNA missing exons 2 
and 3. 
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Figure 16. Sequence of the 306 bp PCR product amplified from 
cathepsin B cDNA in A375M cells. The 306 bp PCR product, 
obtained as described in Figure 15, was cloned into EcoRI and 
HindIII sites of pBluescript vector, and sequenced. The 
complete sequence of several positive clones revealed that 
they arose from cathepsin B transcript which lacked ·exons 2 
and 3. A portion of a representative sequence corresponding 
to the exon 1 - exon 4 junction is shown. 
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exon 3, encoding the signal prepeptide and part of the 
activation propeptide. Reverse transcription and PCR 
amplification was next used to confirm that human tumors 
contain a corresponding mRNA which contains the remainder of 
the procathepsin B coding sequence and the 3'-UTR present in 
other cathepsin B messages (Figure 17). For the 
amplification, the 5' primer (sense primer) was complementary 
to 9 nucleotides on each side of the exon 1 - exon 4 junction, 
and the 3' primer (antisense primer) was complementary to a 20 
nucleotide sequence present in the flanking 3' untranslated 
region of all known, full length cathepsin B mRNAs {Chan et 
al. 1986). cDNA templates prepared from PC3M cell RNA, and 
the plasmids phCB79-2 and phCB79-2-2. 3, were included to 
verify the specificity of the sense primer for the exon 1-exon 
4 junction. Previous RNase protection studies were unable to 
detect any cathepsin B transcripts in PC3M that were missing 
exon 3; plasmid phCB79-2 harbors a full length cathepsin B 
cDNA, including the complete 3 '-UTR of the 2. 3 kb human 
cathepsin B mRNA; and plasmid phCB79-2-2.3 is identical to 
phCB79-2 except it is missing exons 2 and 3. The 934 bp PCR 
product, obtained with phCB79-2-2.3 as a template, is 
indistinguishable in size from the PCR products obtained with 
the cDNAs from the two human melanomas variants, A375M and 
A375P. The identity of the PCR products which were amplified 
from cathepsin B cDNA was confirmed by hybridization with 
human cathepsin B cDNA. 
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F. In Vitro Translation of variant cathepsin B mRNA 
RNase protection assays have shown striking differences 
in the relative abundances of cathepsin B mRNAs which differ 
in their 5 1 -ends in normal human tissues and in human tumors. 
Exon 2, which is more frequently absent from the 5'-UTRs of 
cathepsin B mRNAs from human tumors, has features which can 
affect the translational efficiency of the mRNA. It extends 
the length of the 5 1 -UTR, contains adjacent start and stop 
codons upstream of the normal start site, it is GC rich, and 
computer analysis indicates the potential for the formation of 
secondary structure between a region of exon 2 and a nearby 
downstream sequence. Thus the cathepsin B mRNAs which differ 
in their 5 1 -UTRs may vary in their ability to direct protein 
synthesis. A cathepsin B transcript lacking exon 3 has also 
been found in melanoma cells, and solid colon and breast 
carcinomas. Since exon 3 contains the translation start site, 
and encodes the signal prepeptide and 7 residues of 
propeptide, it was unclear whether such transcripts containing 
an exon 1 - exon 4 splice junction would be translationally 
active. However, there is an in-frame methionine codon, 
corresponding to amino acid 52 in preprocathepsin B, which 
potentially could be used for translation initiation. To 
determine the translational activities and translatability of 
the various human cathepsin B mRNAs which differ in their exon 
composition, an in vitro transcription and reticulocyte lysate 
translation system was used as described in Methods. 
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The SP6 promoter in pGEM-2 vector has been used to 
generate specific transcripts with biological activity (Melton 
et al. 1984). Cathepsin B cDNAs with different exon 
composition in their 5'-ends were cloned into the EcoRI site, 
adjacent to the SP6 promoter as described in Methods. phCB79-
2, phCB79-2-2 and phCB79-2-2. 3 were used to generate the 
corresponding cathepsin B mRNA species. Cathepsin B mRNA from 
phCB79-2 contains the longer 5'-UTR, the entire 
preprocathepsin coding sequence, and the shorter 3 '-UTR. 
Cathepsin B mRNA from phCB79-2-2 is the same as that from 
phCB79-2 except that it has shorter 5 1 -UTR lacking exon 2. 
Cathepsin B mRNA from phCB79-2-2.3 is the same as that from 
phCB79-2 except that it contains the shorter 5'-UTR, and is 
also missing exon 3 encoding the prepeptide and 25 residues of 
the propeptide. Translation from the next in-frame methionine 
codon should produce a protein lacking the signal peptide and 
34 of the 62 residue propeptide. Capped mRNAs transcribed in 
vitro were examined by electrophoresis on an agarose gel, 
transferred onto a Nytran filer, and the filter was hybridized 
with human cathepsin B cDNA. The autoradiogram in Figure 18 
shows that essentially all of the transcripts were full length 
and of the expected size. Phenol/chloroform extraction and 
ethanol precipitation did not cause the degradation and loss 
of the transcripts. These transcripts were used for in vitro 
translation in the reticulocyte lysate in the presence of 355-
methionine. 
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Translation activities were determined by varying both 
RNA template concentration and incubation time for the 
translation reaction. The results were expressed both as the 
rate of labeled methionine incorporation at constant template 
concentration and as the specific activity of the template 
(incorporated methionine/ng RNA) at constant time. 35S-
methionine labeled protein was precipitated with 
trichloroacetic acid, and radioactivity measured. Figure 19 
shows the translational activities of two cathepsin B mRNAs 
with or without exon 2 with respect to the amount of RNA and 
time of incubation at 30°C. From this figure it can be seen 
that cathepsin mRNA with the shorter 5 1 -UTR, the major isoform 
from tumors (phCB79-2-2) is about twice as active as the mRNA 
with the longer 5'-UTR, the major isoform from normal tissues 
(phCB79-2). 35S-methionine labeled protein was also analyzed 
by sos electrophoresis and autoradiography. The protein yield 
from cathepsin B mRNA with the shorter 5'-UTR (phCB79-2-2) was 
higher than that from the mRNA with the longer 5 1 -UTR (phCB79-
2) (Figure 20). Figure 20 also shows a single major band of 
the size expected (approx 37 kDa) for nonglycosalated form of 
preprocathepsin B (339 amino acids) (Chan et al. 1986). The 
results showed in Panel B were same as those in Panel A, 
except varying amount of RNA template was used, and the 
incubation time was 1 hour. 
In order to study the translation potential of cathepsin 
B mRNA lacking exon 3, the synthetic RNA missing exon 2 and 
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Figure 19. Rates of in vitro translation of synthetic 
cathepsin B mRNAs containing variant 5 1 -UTR 
A 
4000 
'E 
c. 
£ 
c: 3000 0 
·;:; 
co 
.... 
0 
c. 
.... 
0 
u 2000 c: 
CD 
c: 
·2 
0 
1: 1000 ... C1' 
~ 
CJ) 
Ill 
M 
- 0 
0 100 200 300 
RNA (ng) 
8 
5000 
~ 
a 
£ 
c: 4000 
0 
·;:; 
co 
.... 
0 
a. 3000 
.... 
0 
u 
c: 
./ C1' 2000 c: ·2 0 
·;:: 
t "::; C1' 1000 ~ C/) Ill M 
- 0 
0 30 60 
Time (minutes) 
93 
Figure 19. Rates of in vitro translation of synthetic 
cathepsin B mRNAs containing variant 5 1 -UTRs. Panel A, the 
specific activities of the two variant templates were 
determined by incubating reticulocyte lysates for 60 min with 
the indicated concentrations of capped cathepsin B synthetic 
RNAs as described in Methods. The amount of [ 35s] L-methionine 
incorporated into trichloroacetic acid-insoluble products was 
measured with a liquid scintillation spectrometer. Panel B, 
the effect of time on [ 35S]L-methionine incorporation into 
trichloroacetic acid-insoluble products was measured as 
described for panel A using 300 ng of template in a final 
volume of 50 µl. Closed circles, mRNA template used in the 
translation was transcribed from clone phCB79-2-2 lacking exon 
2; open circles, from clone phCB79-2 containing exon 2. 
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Figure 20. SOS-PAGE electrophoresis analysis of in vitro 
translation products from cathepsin B mRNAs with and without 
exon 2. synthetic capped cathepsin B mRNAs were incubated 
with a reticulocyte lysate at J0°C as indicated. Five µl of 
the in vitro translation reaction mixture were then 
electrophoresed on a 10% polyacrylamide-SDS gel and 
autoradiographed. phCB79-2-2, RNA template transcribed from 
phCB79-2-2 lacking exon 2; phCB79-2, RNA template from phCB79-
2 containing exon 2; control, no RNA template added to the 
translation reaction. Panel A, JOO ng of synthetic capped 
cathepsin B mRNAs in 50 µl of a reticulocyte lysate were 
incubated for the time indicated. Panel B, the indicated 
amounts of synthetic capped cathepsin B mRNAs in 50 µl of 
reticulocyte lysate were incubated for 1 hour. 
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3 from phCB79-2-2.3 was also translated in vitro in 
reticulocyte lysate, and analyzed by SOS-electrophoresis and 
autoradiography. Figure 21 compares the translation products 
of all three cathepsin B transcripts containing variant 5'-
ends. Not only can the transcript missing exons 2 and 3 
(phCB-2-2.3) be translated in vitro, it is seen to be much 
more active than the other two isoforms. A densitometric scan 
of the autoradiogram in Figure 21 revealed that mRNA obtained 
from phCB79-2-2.3 was translated nearly 4 times more 
efficiently than phCB79-2-2 and nearly 8 times more 
efficiently than phCB79-2. Second, the resulting product is 
of the expected size (about 32 KDa) for translation initiation 
from the first methionine codon in exon 4 (288 amino acids). 
G. Refolding of a Truncated cathepsin B Produced by the In 
vitro Translation of mRNA Lacking Exons 2 and 3 
Reticulocyte lysates appear to be able to translate 
message lacking exons 2 and 3 from a second in-frame 
methionine codon (residue 52). The expected 32,000 dalton 
protein product is obtained which should lack the signal 
peptide and first 34 residues of the 62 amino acid propeptide 
region. To determine if this product can be folded to produce 
a native structure, it was treated in one of two ways: with an 
"oxido-shuffling" buffer containing glutathione disulfide and 
reduced glutathione to facilitate disulfide bond formation 
(Jaenicke and Rudolph, 1989) ; and with decreasing 
concentration of guanidinium hydrochloride as described in 
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Methods (Hager and Burgess, 1980; Vinson et al. 1988). The 
ability to acquire enzymatic activity is a highly stringent 
test of protein folding into a native conformation. The 
results in Figure 22 demonstrate that the missing propeptide 
region of the 32,000 dalton protein product is not essential 
for correct folding and acquisition of enzymatic activity. In 
vitro translation reactions which lacked the synthetic mRNA 
templates gave no activity under any of the refolding 
conditions tried (data not shown) . 
No systematic study was made of the conditions necessary 
to optimize the in vitro folding of the 32,000 dalton 
translation product. Thus, the maximum recovery of activity, 
obtained by dialysis against decreasing concentrations of 
guanidinium hydrochloride at intervals of 30 minutes, is still 
likely to be a lower limit. Using kinetic constants reported 
for Z-Arg-Arg-NMec hydrolysis by rat cathepsin B (Tchoupe et 
al. 1991), and the amount of 35S-methionine incorporated into 
TCA precipitable products, we estimate that as much as 2% of 
the synthetic truncated protein may have acquired a native 
structure. This level was easily measured by the standard 
cathepsin B assay. Also noteworthy is our finding that the 
guanidinium hydrochloride treated product was active (33%) 
prior to treatment with pepsin to remove the remainder of the 
activation propeptide. Either the loss of the entire 
activation propeptide is not needed for activation, or some of 
the enzyme underwent autolysis during folding which removed 
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Figure 22. Refolding of a truncated cathepsin B produced by 
the in vitro translation of mRNA missing exon 2 and 3. Capped 
synthetic mRNA, prepared with plasmid phCB79-2-2.3 as a 
template, was translated by a reticulocyte lysate as described 
in Methods. Refolding was initiated by sequential dialysis 
against decreasing concentrations of guanidinium hydrochloride 
with buffer changes at 10 or 30 min intervals, or by treatment 
with a glutathione disulfide/reduced glutathione "oxido-
shuffling" buffer. Enzymatic activity is expressed as fmol of 
7-amino-4-methylcoumarin (AMC) released from Z-Arg-Arg-NMec 
per min per µg of synthetic mRNA translated. Activity was 
measured before and after treatment with pepsin to remove the 
remainder of amino-terminal propeptide. No activity was 
observed when synthetic mRNA was withheld from the translation 
reaction. 
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the remainder of the propeptide. The "oxido-shuffling" 
treatment of the in vitro translated product did not yield an 
active enzyme species. 
CHAPTER V 
DISCUSSION 
A. Multiple Forms of Cathepsin B Transcripts in Human Tissues 
Cathepsin B cDNA cloned from normal human kidney and the 
hepatoma cell line, HepG2, are heterogeneous (Chan et al. 
1986; Gong et al. 1993) . Northern blotting revealed the 
presence of 2.3 and 4.0 Kb transcripts (Figure 11). Analysis 
of the cloned cDNAs from both sources has further identified 
four cathepsin B transcript types as shown in Figure 23. In 
this present work, I have also identified a fifth type which 
is present in some human tumors, by using a combination of PCR 
and RNase protection assays. Transcript type 1 ( 4. O Kb) 
contains a 237 nt 5' untranslated region (5'-UTR), 1017 nt 
encoding preprocathepsin B, and about a 2800 nt 3'-UTR, while 
type 2 is identical to type 1 except for the deletion of an 88 
nt segment in the 5 1 -UTR (Figure 23). Transcript types 3 and 
4 (2.3 Kb) contain a 789 nt 3'-UTR. The types 3 and 4 differ 
in that type 4 has the same 88 nt deletion in the 5'-UTR 
found in the type 2 transcript. The transcript type 5 has the 
88 nt deletion which is found in the transcripts type 2 and 4, 
and also has an additional 151 nt deletion corresponding to 
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Figure 23. Variant cathepsin B transcripts in human tissues. Overlapping cDNA 
clones corresponding to types 1, 2, 3, and 4 were isolated from human kidney and 
HepG2 phage libraries. The type 5 transcript was cloned from human melanoma cells 
and characterized by PCR as described in the text. The small open box indicates the 
exon 1. The solid box indicates the 88 nt 5' untranslated segment which was deleted 
in transcript types 2, 4, and 5. The type 5 transcript also has an additional 151 
nt deletion corresponding to the signal peptide (S) and 7 amino acid residues of the 
propeptide (P). The hatched box indicates the alternative 3' untranslated region. 
The part of the 3 1 untranslated region in the transcript types 1 through 5, which is 
common to all full length cathepsin B mRNAs, is also shown. The remainder of the 3' 
untranslated region in the type 5 transcript has not been characterized. 
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peptide and 25 amino acid residues of the 
The 3'-UTR of the type 5 transcript has not yet 
been identified. The preprocathepsin B coding sequence was 
identical in all transcripts except for type 5 which lacked 
the exon encoding signal peptide and 25 residues of the 
propetide. 
Cloning and sequencing the human cathepsin B gene 
demonstrated that the multiple cathepsin B transcripts were 
derived from alternative processing of the pre-mRNA (Gong et 
al. 1993). Figure 24 shows the organization of the human 
cathepsin B gene. Phage AhCB107 contained a 11,500 bp insert 
which included the first two exons, which corresponded to the 
5' untranslated sequences. Phage AhCB102 contained a 13,500 
bp insert which included the entire coding sequence of 
preprocathepsin B divided into 9 exons numbered 3-11, and 
contained alternative 3 1 -UTRs located in exon 11 and exon 12. 
Thus, RNA processing at a cryptic intron donor site located in 
exon 11 and splicing to exon 12 deleted the first 
polyadenylation signal and generated the longer alternative 
3'-UTR found in transcript types 1 and 2. In contrast, the 2.3 
Kb transcripts (types 3 and 4) are terminated after the 
polyadenylation signal in exon 11. The deleted 88 nt 5' 
untranslated sequence found in transcript types 2 and 4 is due 
to exon skipping in which exon 1 is spliced directly to exon 
3. The 239 nucleotide deletion from the 5 1 end of transcript 
type 5 is also due to exon skipping in which exon 1 is spliced 
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Figure 24. Organization of human cathepsin B gene. The introns and exons are shown. 
The solid areas are the regions which encode preprocathepsin B. Phage AhCB107 
contains a 11, 500 bp insert which include first two exons containing the 5' 
untranslated region. Phage AhCB102 contains a noncontiguous 13,500 bp insert which 
includes the remaining 9 exons numbered 3-11. Also shown are restriction sites. 
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directly to exon 4. 
The nucleotide sequences of the cathepsin B gene at all 
the exon - intron junctions conform to the canonical GT/AG 
rule (Table 4) (Breathnach and Chambon, 1981), so that the 
generation of cathepsin B transcripts with variant 5 '-ends can 
not be explained simply as the result of a poor splice donor-
acceptor pair between exons 1 and 2, and between exons 2 and 
3. Similarly, the generation of cathepsin B mRNAs with 
variant 3'-UTRs can not be explained as being due to a poor 
splice donor-acceptor pair between exons 11 and 12. Factors 
which regulate alternative splice selection will be described 
later. 
In addition to these five types of cathepsin B 
transcripts in Figure 23, other transcripts have been 
reported. Human colorectal tumors contain low levels of two 
additional messages of 1.5 Kb and 3 Kb (Murnane et al. 1991). 
Human osteoclastomas, which also consist of large numbers of 
apparently normal osteoclasts, contain 2.4, 1.9 and 1.2 Kb 
cathepsin B-related mRNAs (Page et al. 1992) . The origins and 
sequences of these transcripts are unclear. In my studies, 
transcripts smaller than 2.3 Kb were not detected by Northern 
blot analysis. 
Multiple forms of cathepsin B transcripts have also been 
found in murine melanomas (Qian et al. 1989). Murine B16 
melanoma cells contain three transcripts for cathepsin B, a 
2. 2 Kb form also seen in normal tissues, and two larger 
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Table 4. Exon-intron organization of the human cathepsin B 
gene 
exon exon 5'splice 
size donor 
5' UT 
1 124 bp CGCTGGgtgag •.. 
5 1 UT 
2 88 CGAGTAgtaag .•. 
TrpGln 
3 151 TGGCAGgtagg .•• 
GlnArg 
4 86 CCAGAGgtgag ••. 
CysTrp 
5 115 TGCTGGgtaag .•• 
AspGly 
6 119 GGACGGgtaag ..• 
HisVal 
7 86 CATGTAGgtaag ... 
HisTyr 
8 114 CACTACGgtaag ... 
Lysser 
9 117 AAGTCAGgtgct ... 
AspAsn 
10 129 GACAATGgtgag ... 
3' UT 
11 142• ATCGGGgtaga ... 
12 2700 
in tr on 
size 
3500 bp 
5000 
820 
1450 
1750 
750 
230 
470 
1380 
470 
823 
3'splice 
acceptor 
5 1 UT 
••. tcccagGCTGGT 
5' UT 
... ctccagGTGGAT 
AlaGly 
•.• ttccagGCCGGG 
ValMet 
... atccagAGTTATG 
AlaPhe 
... ctgcagGCCTTC 
CysAsn 
... tttcagCTGTAAT 
GlyCys 
•.. catcagGGTGCA 
GlyTyr 
... ttccagGATACA 
GlyVal 
••• tttcagGAGTGT 
GlyPhe 
. .. tcccagGCTTCT 
3' UT 
. .. ctgcagAGAATC 
*Exon 11 = 886 bp for 2.3 Kb cathepsin B mRNAs (types 3 and 4) 
in which the alternative splice site donor site is not 
utilized. UT stands for untranslated. 
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transcripts of 4 Kb and 5 Kb only observed in the melanomas. 
Recently, a 4 Kb message for cathepsin B has been reported in 
metastatic ras-transf ormed NIH 3T3 cells (Chambers et al. 
1992). Moin et al (1989), employing a human cathepsin B cDNA 
probe, have also observed a 4 Kb transcript in normal mouse 
liver. However, Qian et al (1989; 199lc) were unable to 
detect 4 and 5 Kb messages for cathepsin B in normal mouse 
liver, kidney, and spleen using either a cathepsin B cDNA 
probe or a fragment from the 3 1 -end of the mouse cathepsin B 
gene specific for the larger transcripts from melanoma cells. 
These variant transcripts were found to encode the same 
cathepsin B percursor protein but to differ in the lengths of 
their 3'-untranslated regions (Qian et al. 1991b; Qian et al. 
1991c). The use of alternative polyadenalation signals, which 
is also seen with the human cathepsin B gene, explains the 
differences between these variant cathepsin B transcripts in 
mouse melanomas. 
B. Levels of Expression of variant cathepsin B mRNAs in Human 
Normal Tissues and Tumors 
Many reports have indicated an association between 
cathepsin B and cancer. Elevated levels of cathepsin B have 
been correlated with increased metastatic potential or 
invasiveness in a variety of tumors from humans (Pietras and 
Roberts, 1981; Recklies et al. 1982; Dufek et al. 1984; 
Watanabe et al. 1989; Sheahan et al. 1989} and rodents, (Sloane 
et al. 1982; Koppel et al. 1984; Sloane et al. 1986). Indeed, 
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elevated cathepsin B expression has been thought to be a 
marker of the tumorigenic and/or malignant state (Sloane et 
al. 1982; Koppel et al. 1984). Most of these studies used 
enzymatic or immunochemical methods to detect and quantitate 
the enzyme. However, using activity measurements to estimate 
enzyme levels suffers from uncertainties concerning the 
specificity of the substrates, and the presence of different 
amounts of endogenous inhibitors and activators in different 
tissues which may lead to an under- or over-estimation of the 
enzyme. Immunochemical methods may be compromised by the 
cross-reactivity between closely related cysteine proteinases 
(Wiederander and Kirschke, 1986). In this present study, I 
have employed cDNA for human cathepsin B to examine its 
expression in normal human tissues and cultured melanoma cells 
of different metastatic properties. The mRNA levels for 
melanomas A375P (parental, poorly metastatic) and A375M 
(metastatic) are 1.5 and 2.3 fold higher respectively than 
that for kidney and spleen, the tissues with the highest 
expression of cathepsin B among the five normal tissues 
studied. This result is in agreement with the reports of 
enhanced cathepsin B activities observed in a variety of 
tumors such as murine fibrosarcomas (Keren and LeGrue, 1988), 
human liver cancer (Dufek et al. 1984), human ovarian 
carcinoma (Mort et al. 1981), human genital tract cancer 
(Pietras and Roberts, 1981) and human breast carcinoma 
(Recklies et al. 1982). The elevated levels of cathepsin B 
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mRNA in human melanoma cells suggested that in these cells 
cathepsin B expression is regulated, at least in part, at the 
level of transcription and/or mRNA stability. 
Post-transcriptional mechanisms may also be involved in 
the regulation of cathepsin B expression. As mentioned above, 
cathepsin B mRNA is heterogeneous due to differences in 
processing of the 5'- and 3'-ends. The selection of variant 
5' splice donor sites in exon 11 produces messages which 
differ in the lengths of their 3 '-UTRs. Although the 
functional significance of mRNAs which vary in their 3'-UTRs 
is not known in most cases, modification at the 3'-ends of 
messages have been shown to affect rates of mRNA turnover 
(Brawerman, 1987; Ross, 1988) and ability to be translated 
into protein (Kruys et al. 1987). We have shown that both 4. O 
Kb (types 1 and 2 in Figure 23) and 2.3 Kb transcripts (types 
3 and 4 in Figure 23) were expressed in the normal tissues we 
examined and in cultured melanoma cells. There may be subtle 
differences in the expression of the 2.3 Kb transcript versus 
4. o Kb transcript in certain tissues (Table 2) . As large 
differences in the relative abundances of the 2.3 and 4.0 Kb 
transcripts were not observed between normal tissues and tumor 
cells, the regulatory significance of these two cathepsin B 
mRNA forms is unclear at present. The significance of the 
longer 3 1 -UTRs in the 4.0 kb and 5.0 kb cathepsin B mRNAs in 
murine tumors also remains unknown. 
Human cathepsin B transcript types 2 and 4 (Figure 23) 
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were found to result from the occasional skipping of exon 2 
during pre-mRNA processing, resulting in an 88 nt deletion 
from their 5'-UTRs. Differences in the length of the 5'-UTR 
of the messages has also been shown to affect mRNA stability 
(Brawerman, 1987) and translation efficiency (Young et al. 
1981; Waterhouse et al. 1990; Horiuchi et al. 1990; Manzella 
and Blackshear, 1990; Foyt et al. 1991; Bares et al. 1991; Kim 
et al. 1992). In this study, I have observed a greater than 
30 fold difference in the relative levels of the two types of 
messages in normal human tissues (Table 3). Thus, cathepsin 
B mRNAs which contain the truncated 5'-UTR were barely 
detectable in skeletal muscle, but were the majority in liver 
and spleen. Human tumors not only contained higher levels of 
mRNA for cathepsin B, but the preponderant messages in tumors 
also contained the shorter 5'-UTR (Table 3). These 
observations suggest that alternative processing of the 5'-UTR 
of cathepsin B pre-messages may contribute to the regulation 
of cathepsin B expression. The differential expression of 
mRNA with variant 5'-UTR in different tissues has been 
demonstrated for some other genes, for example, human insulin-
like growth factor II gene (Shen et al. 1988), human 
complement protein C2 (Horiuchi et al. 1990), mouse complement 
factor B gene (Nonaka et al. 1989), mouse a-amylase gene (Shaw 
et al. 1985) and Drosophila alcohol dehydrogenase gene 
(Benyajati et al. 1983; Bond and Davidson, 1986). 
Another potentially significant finding in this study is 
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the presence in human breast and colon carcinomas and in human 
melanoma of a fifth type of cathepsin B message which lacks 
exon 2 (non coding) and also exon 3 (encoding the 17 residue 
signal peptide and 25 residues of the activation propeptide) 
(Figure 12 and 15). The 5'-end of this transcript was cloned 
by PCR techniques (Figure 15) and its identity was confirmed 
by sequencing (Figure 16). Reverse transcription and PCR 
amplification confirmed that this transcript contained the 
remainder of the procathepsin B coding sequence and the 3'-UTR 
characteristic of normal cathepsin B transcript (Figure 17). 
Further characteristic of this transcript and its significance 
in the regulation of cathepsin B expression are discussed 
below. 
c. Mechanisms of Alternative Splicing 
The mechanisms involved in the regulation of alternative 
splicing are the subject of intense study. Though not 
presently well understood, several themes are emerging. 
Alternative splicing often appears to be acheived by subtle 
variations of the basic mechanisms of RNA processing. Many 
studies have shown that differential splice site utilization 
involves the selection of a variant of a cis element, such as 
the consensus sequence around the 5' and 3' splice-site and 
around the branch point (Ruskin et al. 1985; Aebi et al. 1986; 
Smith and Nadal-Ginard, 1989). In the case of human cathepsin 
B, alternative splicing at the 5' end is not due to the 
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selection of a variant consensus sequence at the 5' and 3 1 
splicing sites, as discussed above. 
Regulation of alternative splicing also involves 
differences in cellular trans-acting factors that usually 
assemble with the transcript into a splicing complex. Cases 
of alternative splicing , where identical pre-mRNA transcripts 
give rise to different mRNAs in a cell-type or developmental 
stage-specific manner, clearly demonstrate that the splicing 
environment of different cells varies for these transcripts 
(Breitbart and Nadal-Ginard, 1987; Wieczorek et al. 1988). 
The different distributions of variant cathepsin B mRNAs 
resulting from alternative splicing in human tissues and 
tumors are more likely due to differences in the cellular 
trans-acting factors which are involved in pre-mRNA 
processing. 
The trans-acting factors which have been identified to be 
associated with pre-mRNA processing include snRNP, hnRNP 
proteins and several other protein factors. Ul, U2, U4/U6, 
and us snRNPs are the most extensively characterized 
functional components of the spliceosome where pre-mRNA 
splicing takes place (Padgett et al. 1983; Krainer et al. 
1984; Kramer et al. 1984; Black et al. 1985; Black et al. 
1985; Chabot et al. 1985; Black and Steitz, 1986) . Some 
snRNAs show sequence heterogeneity (Lund, 1988) and are 
regulated in a developmental and tissue-specific manner (Kato 
and Harada, 1985; Lund et al. 1985; Lund and Dahlberg, 1987; 
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Fu et al. 1988; Krof et al. 1988). Some studies of snRNP 
proteins indicated than these could be modified by 
phosphorylation (Woppman et al. 1988). Thus, differentially 
modified snRNP protein components, as well as snRNA-sequence 
heterogeneity may allow for functionally distinct, tissue-
specif ic or developmentally regulated snRNPs which could 
permit cells to tune the existing splicing machinery and 
facilitate differential splice-site utilization. Alterations 
in Ul snRNP levels have also been shown to affect splice site 
selection in both artificial and natural pre-mRNAs (Green, 
1991). 
In addition to the above snRNPs, several protein factors 
have been shown to be required for splicing, such as hnRNP 
proteins, Al, A2, Bl, B2, Cl, C2, and D, which were associated 
with hnRNA (Dreyfuss, 1986; Chung and Wooley, 1986; Ruby and 
Abelson, 1991; Conway et al. 1988; Gil et al. 1991; Patton et 
al. 1991), and splicing factor SF2 (Krainer et al. 1990a,b). 
Recently, Mayeda and Krainer (1992) reported that hnRNP Al and 
splicing factor SF2 could regulate alternative pre-mRNA 
splicing in vitro. They demonstrated that changes in the 
relative concentrations of SF2 and hnRNP Al could modulate 
alternative 5' splice site selection in vitro in some natural 
pre-mRNAs, such as the adenovirus ElA pre-mRNA. These 
splicing factors did not appear to operate in a substrate-
specif ic manner, but rather they had a general effect on the 
polarity of alternative 5' splice-site selection. Thus, an 
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excess of SF2 over hnRNP Al consistently resulted in 
activation of proximal 5' splice sites, whereas an excess of 
hnRNP Al over SF2 generally favors distal 5' splice sites. If 
regulation of alternative 5' splice-site selection by hnRNPAl 
and SF2 takes place in vivo, the concentration or the 
activities of one or both of these factors is predicted to be 
subject to tissue-specific, developmental, or physiological 
control. Interestingly, the intracellular concentration of 
hnRNP Al has been reported to increase in proliferating versus 
quiescent cells (Lestourgeon et al. 1977; de Koch et al. 1981; 
Celis et al. 1986; Planck et al. 1988). In addition, specific 
transformation-related changes in the alternative splicing 
patterns of several cellular genes have been reported (Boris 
et al. 1987; Zardi et al. 1987; Goodwin et al. 1991). This 
present study also demonstrates that the human cathepsin B 
gene can undergo changes in splicing patterns in tumor cells. 
These results together with the role of hnRNP Al and SF2 in 
the alternative splicing suggested that quantitative 
differences in hnRNP Al and SF2 might contribute to these 
transformation-related changes in gene expression. The effect 
of hnRNP Al and SF2 on the changes of alternative splicing in 
human cathepsin B pre-mRNA among different normal tissues and 
tumors can be tested by quantification of hnRNP Al and SF2 in 
these tissues. 
Another possibility for different distribution of variant 
human cathepsin B mRNA in normal tissues and tumors may be 
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differences in cellular factors which affect stability of the 
respective mRNAs. This alternative hypothesis can also be 
tested directly by measuring the rates of decay of the variant 
messages. 
D. Comparison of Translational Activities of cathepsin B 
mRNAs with variant S'-OTRs 
As discussed above, multiple forms of cathepsin B cDNAs 
which differ in their lengths of 5 1 -UTRs have been cloned. 
The results of RNase protection assays confirmed the presence 
of cathepsin B mRNAs with different 5'-UTRs in human normal 
tissues and tumors, and also revealed that the ratio of 
transcripts with a full length 5'-UTR to truncated forms 
varied widely among normal human tissues, and between normal 
tissues and tumors. Forms containing a truncated 5 '-UTR 
(lacking exon 2) were much more abundant in human tumors than 
that in normal tissues. Many studies have demonstrated that 
5'-UTR can affect translational capacity of a transcript. To 
investigate the possible role of the 5'-UTR of cathepsin B 
transcripts on their translation, the translation efficiencies 
of cathepsin B mRNAs differing in their 5'-UTRs were studied 
in this present work. Transcripts lacking exon 2 were twice 
as active as those containing exon 2 in an in vitro 
translation assay employing synthetic capped RNAs and a 
reticulocyte lysate (Figure 19 and 21), suggesting that the in 
vitro translation of cathepsin B is under the control of the 
5 1 -UTR. These results together with those from the RNase 
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protection assays suggest that alternative splicing of the 5 ' -
UTR of cathepsin B may play a role in the regulation of 
cathepsin B expression. 
The mechanisms involved in regulation of translation by 
5'-UTR have been studied, and three properties of the 5'-UTR 
have been shown to influence the translatability of an mRNA 
(Kozak, 1991a,b}: (l} the presence of GC rich sequences which 
can modify secondary structure; (2) the presence of short open 
reading frames; (3) the length of the 5'-UTR. Rao et al. 
(1988} demonstrated that 5 '-UTR of c-sis/platelet-derived 
growth factor 2 (PDGF-2} transcript exerted an inhibitory 
effect on translation. This transcript contains a long 5 '-UTR 
that is highly GC rich and can form stable secondary 
structures. Deletion of the 5'-UTR resulted in as much as a 
10 fold increase in c-sis PDGF-2 expression in vivo. There is 
growing evidence that expression of a gene may be negatively 
modulated at the translational level by stable secondary 
structures in the 5'-UTR of mRNA. It has been observed that 
the translation rate of ornithine decarboxylase mRNA 
containing full length 5'-UTR was much lower than that of mRNA 
containing no 5' lead sequence in both in vivo and in vitro 
assays (Grens and Scheffler, 1990; Manzella and Blackshear, 
1990}. This effect was shown to be due to the GC-rich segment 
of the UTR which has the potential to form a very stable 
hairpin structure. The effect of secondary structure in the 
5 '-UTR on the translation of a transcript has also been 
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studied by insertion of a synthetic oligonucleotide designed 
to create a hairpin structure upstream from the ATG initiation 
codon of preproinsulin transcripts (Kozak, 1986; Kozak, 1989). 
The results revealed that the hairpin structures in the range 
of stability of aG = -so kcal/mol could reduce the efficiency 
of translation 85 to 95%, whereas weaker secondary structures 
(aG = -30 kcal/mol) did not affect the rate of translation. 
It was thought that the weaker secondary structure could be 
readily melted by functional 40S ribosomal subunits which are 
presumed to bind to the capped S' end of an mRNA and migrate 
linearly until reaching the first AUG codon where they are 
joined by a 60S subunit. In contrast, stable secondary 
structure could block the migration of the 40S subunits. 
Another factor which can affect translational efficiency 
is the presence of an open reading frame in the 5'-UTR. The 
occurrence of an upstream AUG start codon which is followed 
shortly by a termination codon to create a small open reading 
frame at the s•-end of the mRNA nearly always reduces the 
efficiency of translation initiation from a downstream AUG 
codon. Impairment of translation by an open reading frame 
burdened 5' untranslated leader sequence has been reported for 
many mRNAs, such as rat insulin-like growth factor I (Foyt et 
al. 1991; Lowe et al. 1987), rat farnesyl pyrophosphate 
synthetase (Teruya et al. 1990), rat thyroid hormone receptor 
(Murray et al. 1988), human interleukin-? (Young et al. 1991), 
human and mouse interleukin-2 receptor (Weinberg and Swain, 
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1990), human fibroblast growth factor-5 (Bares et al. 1991) 
and transforming growth factor-P3 (Arrick et al. 1991). The 
simplest explanation is that, after a ribosome translates the 
upstream open reading frame , the 405 ribosomal subunit may 
reinitiate at another AUG codon downstream. The inhibitory 
effect of the upstream AUG codon may be attributable to the 
inefficiency of this reinitiation. Reinitiation could be 
inefficient for a variety reasons. One possibility is that 
ribosomes frequently dissociate from mRNA at the upstream 
termination codon. A related possibility is that ribosomes 
remain on the mRNA but are unable to recruit other components 
of translation initiation before reaching the second 
downstream open reading frame. A third mechanism of 
inhibition can be imagined in which ribosomes become stalled 
at the upstream open reading frame, thereby blocking further 
scanning downstream (Mueller and Hinnebusch, 1986). 
In addition to secondary structures and open reading 
frames in the 5 '-UTR, the length of 5 '-UTR has also been shown 
to affect the translation of mRNA. The transcript of the 
human complement protein C2 has an unusually long 5 1 -UTR (388 
nt). Deletion of this region resulted in a 10 fold 
enhancement in the translational efficiency of C2 in transient 
eukaryotic cellular assays (Horiuchi et al. 1990). A 
decreased translation rate due to the lengthening of the 5' 
noncoding sequence was also found for the genes of murine 
tissue inhibitor of metalloproteinases (Waterhouse et al . 
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1990), rat guanylate cyclase {Chinkers et al. 1989) and human 
8 globin {Leung et al. 1989). It has been reported that RNAs 
containing a 5'-UTR greater than 200 nt were translated much 
less efficiently than their truncated counterparts by 
eukaryotic ribosomes in vitro {Young et al. 1981). Because in 
most cases the originally long 5 '-UTRs contain sequences which 
can form secondary structures, there is argument that the 
effect of this kind of 5'-UTR on the translation might be due 
to both length and secondary structure. Recently Kozak 
{1991c,d) has used synthetic 5' noncoding sequences which were 
designed to increase the length of the 5'-UTR without 
introducing secondary structure to study the effect of the 
length of 5'-UTR on translation. In contrast to the negative 
effect on translation reported previously, she found that 
lengthening the 5' noncoding sequence of transcripts could 
increase their translational efficiency under conditions of 
translation in reticulocyte lysates. In these cases 
translation efficiency was proportional to leader length in 
the range of 17 to about 80 nucleotide. It seems likely that 
long 5' leader sequences appear to accumulate extra 40S 
ribosomal subunits, which may account for their translational 
advantage. However, the effect on translation of inserting 
more than 80 nucleotides of synthetic sequence prior to the 
AUG codon remains unknown. 
The 88 nt exon 2 of human cathepsin B transcripts, which 
is sometimes spliced out of the 5'-UTR to generate transcript 
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with truncated 5 '-UTR, has features which can affect the 
translation efficiency of the transcript. It extends the 5'-
UTR to 237 nucleotides for full length 5'-UTR, contains an 
adjacent start and stop codon upstream from the normal 
translation start site and is GC rich. In addition, a 
preliminary computer analysis of the secondary structure of 
cathepsin B cDNA indicates that there is a potential for 
formation of a stable stem-loop structure between part of exon 
2 and a nearby downstream sequence. These features may 
explain the decreased translational activity of the cathepsin 
B transcript with the full length 5'-UTR in the in vitro assay 
compared to that of the cathepsin B transcript missing exon 2. 
E. Characteristics of cathepsin B Transcript Missing Exons 2 
and 3 
A significant new finding in this present work is the 
detection in human breast and colon carcinomas and in human 
melanomas of a fifth type of cathepsin B transcript which 
lacks exon 2, noncoding, and exon 3 encoding the 17 residue 
signal peptide and 25 residues of the activation peptide 
(Figure 12, 15, 17, and 24). I have shown that this 
transcript is complete in that it contains the remainder of 
the cathepsin B coding sequence and part of the 3'-UTR which 
is common to all full length cathepsin B mRNAs (Figure 17). 
I have also demonstrated by in vitro transcription and 
translation that the corresponding synthetic message-lacking 
exons 2 and 3 can be translated, possibly from an in-frame 
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internal methionine (residue 52) within the propeptide region. 
The resulting 32 KDa protein product (Figure 22) would lack 
the signal peptide which is required for directing cathepsin 
B to the lysosomes, and the first 34 residues of the 62 amino 
acid propeptide which inhibits enzyme activity. Remarkably, 
this RNA is 4 times more active in the reticulocyte lysate 
than an RNA lacking exon 2, and 8 times more active than the 
RNA containing the full length 5 '-UTR. Furthermore, I 
determined that this truncated product can be folded to 
produce a native structure. 
After treatment of an in vitro translation mixture with 
decreasing concentrations of guanidinium hydrochloride to 
promote refolding, cathepsin B enzyme activity could be 
detected. In contrast, treatment with an "oxide-shuffling" 
buff er to promote disulfide bond formation failed to generate 
an active enzyme. The ability to acquire enzymatic activity 
is a highly stringent test of folding into a native 
conformation. Results in Figure 22 show that the activity 
obtained after dialysis against decreasing concentrations of 
guanidinium hydrochloride is easily detected by the standard 
cathepsin B assay. This demonstrates that the 32,000 dalton 
truncated form of cathepsin B can be refolded to produce an 
active species, and that the missing propeptide region of this 
protein product is not essential for correct folding. I also 
found that treatment of the refolded product with pepsin, to 
remove the remainder of the activation propeptide, increased 
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its activity three fold. We postulated that either the removal 
of the entire activation propeptide may not be necessary for 
activation, or some of the enzyme may undergo autolysis during 
folding which removed the remainder of the propeptide. 
These results indicated that cathepsin B transcripts from 
human tumors which lacks exons 2 and 3 are likely to be 
functional mRNAs. Our ability to ref old the translated 
product of the corresponding synthetic mRNA into an active 
enzyme in vitro increases the likelihood that such message 
would produce a stable, active protein in vivo. Further, we 
can speculate that this molecular form of cathepsin B, missing 
the N-terminal signal peptide, may no longer be targeted to 
the lysosome. 
Cellular transformation and other pathological changes 
can be accompanied by a redistribution of cathepsin B to 
secretory vesicles (Docherty et al. 1984; Saluja et al. 1989; 
Achkar et al. 1990), the plasma membrane (Pietras and Roberts, 
1981; Sloane et al. 1987; Keren and LeGrue, 1988; Weiss et al. 
1990) and the nucleus (Pietras and Roberts, 1981). 
Transformed cells also contain and secrete several different 
molecular forms of cathepsin B including higher molecular 
weight latent and active forms (Recklies et al. 1980; Mort et 
al. 1980; Dufek et al. 1984; Biaci and Knopeel, 1986; 
Petrova-Skalkova et al. 1987; Keppler et al. 1988b; Docherty 
and Phillips, 1988; Maciewicz et al. 1989). Some of these 
undoubtedly reflect alterations in the linked targeting and 
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posttranslational processing of the cathepsin B which result 
in changes in the amount and composition of oligosaccharide 
side chain (Keppler et al. 1988b; Nishimura et al. 1988) and 
the extent of proteolytic modifications (Chan et al. 1986; 
Hara et al. 1988). Our present results also raise the 
possibility that in some human tumors a part of this diversity 
of form and location may be due to alternative splicing of 
cathepsin B pre-mRNA. One can speculate that the putative 
product of a cathepsin B mRNA missing exon 3 could have a 
cytosolic and/or nuclear location and could participate in the 
modulation of cellular activity by the limited proteolytic 
modification of key regulatory proteins. Interestingly, it 
has recently been shown that the product of the c-Ha ras gene 
is structurally homologous to some members of the cystatin 
type II gene family, and can bind to cathepsin B and related 
enzymes with high affinity (Hiwasa et al. 1987; Rawlings and 
Barrett, 1990) . 
CHAPTER Vl: 
SUMMARY 
1. Multiple forms of cathepsin B transcripts, which 
result from alternative processing in the 5' and 3' 
untranslated regions (UTRs), have been identified in normal 
human tissues and human tumors by Northern blot and RNase 
protection assays. 
2. The relative levels of the cathepsin B transcripts 
(2.3 Kb and 4.0 Kb) differing in the lengths of their 3'-UTRs 
has been measured in normal human skeletal muscle, kidney, 
liver, spleen and colon, and in the two human melanoma 
variants A375P and A375M by Northern blot. The ratios of the 
2. 3 Kb transcript to the 4. o Kb transcript only varied by 
about a factor 2, from 2. 8 to 6. 2. Thus, the regulatory 
significance of these two cathepsin B mRNA forms is unclear at 
present. 
3. The relative levels of the cathepsin B mRNAs which 
differ in the lengths of their 5 1 -UTRs were also measured by 
RNase protection assays in normal human skeletal muscle, 
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kidney, liver, spleen and colon, in samples from human colon 
and breast carcinomas, and in several established cultured 
human tumor cell lines, two prostate carcinoma variants, PCJP 
and PCJM, two melanoma variants A375P and A375M, and colon 
carcinoma. The ratios of the transcript lacking exon 2 to 
that containing exon 2 varied widely from less than 0.1 to 3 
for the normal tissues, and from 6.0 to 24 for the tumors and 
tumor derived cell lines. Thus, transcripts with the shorter 
5 '-UTR were much more abundant in tumors than in normal 
tissues. 
3. An in vitro transcription/translation assay was used 
to demonstrate that the cathepsin B transcripts with variant 
5'-UTRs differ in their rates of translation. 
rates are about 2: 1 for mRNAs lacking exon 
containing the full length 5' end. 
The relative 
2 to mRNAs 
4. Human breast and colon carcinomas and human 
melanomas, A375P and A375M, contain a cathepsin B transcript 
which is also missing exon 3 encoding the signal peptide and 
7 residues of the activation propeptide. This transcript is 
complete, and contains the remainder of the cathepsin B coding 
sequence and part of the J'-UTR which is common to all full 
length cathepsin B mRNAs. 
5. An in vitro transcription/translation assay was used 
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to demonstrate that cathepsin B transcripts missing exon 3 
could be translated from an internal methionine codon (residue 
52), producing a 32 KDa product lacking the signal peptide and 
more than half the propeptide. This truncated form of 
cathepsin B should no longer be targeted to the lysosome. 
6. Finally, the translation product from the message 
missing exons 2 and 3 was able to acquire a native-like 
conformation after refolding in vitro. This refolded, 
truncated protein was active against the specific substrate, 
N-benzyloxycarbonyl-L-arginyl-L-arginine-7-amido-4-
methylcoumarin (Z-Arg-Arg-AMC). Treatment with pepsin, to 
remove the remainder of the activation propeptide, increases 
catalytic activity 3 fold. These results indicate that 
cathepsin B mRNA lacking exons 2 and 3 is likely to be a 
functional mRNA. 
These findings suggest that alternative splicing of 
cathepsin B pre-mRNA may be involved in regulating the 
expression and subcellular distribution of cathepsin B in 
human tissues and tumors. 
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